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ABSTRACT

ROLE OF MACHINE LEARNING IN EARLY DIAGNOSIS OF KIDNEY DISEASES
Mohamed Nazih Mohamed Ibrahim Shehata
July 28, 2022

Machine learning (ML) and deep learning (DL) approaches have been used as
indispensable tools in modern artificial intelligence-based computer-aided diagnostic (AIbased CAD) systems that can provide non-invasive, early, and accurate diagnosis of a
given medical condition. These AI-based CAD systems have proven themselves to be
reproducible and have the generalization ability to diagnose new unseen cases with several
diseases and medical conditions in different organs (e.g., kidneys, prostate, brain, liver,
lung, breast, and bladder). In this dissertation, we will focus on the role of such AI-based
CAD systems in early diagnosis of two kidney diseases, namely: acute rejection (AR) post
kidney transplantation and renal cancer (RC).
A new renal computer-assisted diagnostic (Renal-CAD) system was developed
to precisely diagnose AR post kidney transplantation at an early stage. The developed
Renal-CAD system perform the following main steps: (1) auto-segmentation of the renal
allograft from surrounding tissues from diffusion weighted magnetic resonance imaging
(DW-MRI) and blood oxygen level-dependent MRI (BOLD-MRI), (2) extraction of image markers, namely: voxel-wise apparent diffusion coefficients (ADCs) are calculated
from DW-MRI scans at 11 different low and high b-values and then represented as cumuvi

lative distribution functions (CDFs) and extraction of the transverse relaxation rate (R2*)
values from the segmented kidneys using BOLD-MRI scans at different echotimes, (3)
integration of multimodal image markers with the associated clinical biomarkers, serum
creatinine (SCr) and creatinine clearance (CrCl), and (4) diagnosing renal allograft status
as nonrejection (NR) or AR by utilizing these integrated biomarkers and the developed
deep learning classification model built on stacked auto-encoders (SAEs). Using a leaveone-subject-out cross-validation approach along with SAEs on a total of 30 patients with
transplanted kidney (AR = 10 and NR = 20), the Renal-CAD system demonstrated 93.3%
accuracy, 90.0% sensitivity, and 95.0% specificity in differentiating AR from NR. Robustness of the Renal-CAD system was also confirmed by the area under the curve value of
0.92. Using a stratified 10-fold cross-validation approach, the Renal-CAD system demonstrated its reproduciblity and robustness with a diagnostic accuracy of 86.7%, sensitivity
of 80.0%, specificity of 90.0%, and AUC of 0.88.
In addition, a new renal cancer CAD (RC-CAD) system for precise diagnosis of
RC at an early stage was developed, which incorporates the following main steps: (1)
estimating the morphological features by applying a new parametric spherical harmonic
technique, (2) extracting appearance-based features, namely: first order textural features
are calculated and second order textural features are extracted after constructing the graylevel co-occurrence matrix (GLCM), (3) estimating the functional features by constructing
wash-in/wash-out slopes to quantify the enhancement variations across different contrast
enhanced computed tomography (CE-CT) phases, (4) integrating all the aforementioned
features and modeling a two-stage multilayer perceptron artificial neural network (MLPANN) classifier to classify the renal tumor as benign or malignant and identify the malignancy subtype. On a total of 140 RC patients (malignant = 70 patients (ccRCC = 40 and
nccRCC = 30) and benign angiomyolipoma tumors = 70), the developed RC-CAD system was validated using a leave-one-subject-out cross-validation approach. The developed

vii

RC-CAD system achieved a sensitivity of 95.3% ± 2.0%, a specificity of 99.9% ± 0.4%,
and Dice similarity coefficient of 0.98 ± 0.01 in differentiating malignant from benign renal tumors, as well as an overall accuracy of 89.6% ± 5.0% in the sub-typing of RCC.
The diagnostic abilities of the developed RC-CAD system were further validated using a
randomly stratified 10-fold cross-validation approach. The results obtained using the proposed MLP-ANN classification model outperformed other machine learning classifiers
(e.g., support vector machine, random forests, and relational functional gradient boosting)
as well as other different approaches from the literature.

In summary, machine and deep learning approaches have shown potential abilities
to be utilized to build AI-based CAD systems. This is evidenced by the promising diagnostic performance obtained by both Renal-CAD and RC-CAD systems. For the RenalCAD, the integration of functional markers extracted from multimodal MRIs with clinical
biomarkers using SAEs classification model, potentially improved the final diagnostic results evidenced by high accuracy, sensitivity, and specificity. The developed Renal-CAD
demonstrated high feasibility and efficacy for early, accurate, and non-invasive identification of AR. For the RC-CAD, integrating morphological, textural, and functional features extracted from CE-CT images using a MLP-ANN classification model eventually
enhanced the final results in terms of accuracy, sensitivity, and specificity, making the
proposed RC-CAD a reliable noninvasive diagnostic tool for RC. The early and accurate
diagnosis of AR or RC will help physicians to provide early intervention with the appropriate treatment plan to prolong the life span of the diseased kidney, increase the survival
chance of the patient, and thus improve the healthcare outcome in the U.S. and worldwide.
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CHAPTER I
INTRODUCTION

Machine learning (ML) and deep learning (DL) approaches are sub-fields of artificial intelligence (AI) that have shown significant success in many diverse medical imaging applications, such as image segmentation, registration, and classification [1]. They
have been used as indispensable tools in modern AI-based computer-aided diagnostic (AIbased CAD) systems that assist in making decisions regarding medical diagnosis. These
systems can automate the diagnosis, reduce the subjectivity between different radiological
assessments, and improve the diagnostic performance. Traditional ML approaches mainly
depend on hand-crafted features to convert the input data into suitable patterns that could
be used for diagnostic problems [2]. These kind of AI-based CAD systems encompass
segmentation of the intended organ/region of interest, hand-crafted feature extraction, and
classification. Traditional ML classification algorithms that have been widely used in AIbased CAD systems include, but are not limited to: k-nearest neighbors (k-NN), support
vector machine (SVM), linear discriminant analysis (LDA), logistic regression (LR), random forest (RF), Naive Bayes (NB), decision tree (DT), multi-layer perceptron artificial
neural networks (MLP-ANN), and Adaboost. During the last 5-10 years, DL has evolved
as an exciting field through adaptation of MLP-ANN in which the network has many hidden layers [2]. This technique builds a hierarchical data representation (i.e. from less
to more abstracted representations), and thus has the power of learning high-level features from the underlying data [3]. Stacked-auto encoder (SAE) [4, 5] is an example of
DL techniques that has the ability to process thousands of hand-crafted features extracted

1

from input images to obtain a final diagnosis of a given medical condition. Other examples
of DL techniques are convolution neural network (CNN), deep neural networks (DNN),
and generative adversarial networks (GAN), which have been shown to be efficient in AIbased CAD systems dealing with large datasets are . Although they can automatically
extract thousands of features from input images data for classification purposes and avoid
the burden of the hand-crafted features, they are limited by the need for large datasets to be
well-trained. In addition, the automated extracted features are not readily explainable and
need much effort for correlation and interpretation [3, 6]. Those AI-based CAD systems
have proven themselves to be reproducible and have the generalization ability to diagnose
new unseen cases with several diseases and medical conditions in different organs (e.g.,
kidneys, prostate, brain, liver, lung, breast, and bladder). In this dissertation, we will focus
on the role of such AI-based CAD systems in early diagnosis of kidney diseases.
Several kidney diseases might rise up and badly affect the kidneys, which hinder
them from performing their functions in a normal way. These kidney diseases [7] include,
but are not limited to: chronic kidney disease (CKD), acute kidney injury (AKI), acute
tubular necrosis (ATN), kidney stones, acute rejection (AR) post kidney transplantation,
and renal cancer (RC). Early and precise diagnosis of kidney diseases is crucial to provide
an appropriate and timely intervention plan to prevent or mitigate kidney failure. This
dissertation will focus on two of the most contributing kidney diseases, namely: AR and
RC. Chronic kidney disease (CKD) is the 10th leading cause of mortality in the United
States. Approximately 37 million patients are suffering from CKD [8], which if it remains
untreated, will result in progressive damage of the kidney until it develops a fatal condition called end stage kidney disease (ESKD). In 2022, the estimated number of ESKD
patients in the U.S. is ≈ 780,000 [8]. ESKD is treated by blood dialysis and eventually
by kidney transplant. While dialysis helps the patient stay alive, it performs only 10% of
the kidney’s function which leads to dangerous health conditions. Meanwhile, transplan-
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tation is considered a long-term treatment as it prolongs patients’ lives. However, organ
procurement and transplantation is a challenging process. Each month, more than 3,000
patients are added to the kidney transplant waiting list while only 17,500 renal transplants
are performed each year due to the paucity of donor organs [9–11]. In addition, during the
first five years after transplantation, there is a 15% - 27% chance that the immune system
will reject the foreign organ, leading to AR [12]. AR is considered the leading cause of
kidney transplant dysfunction with two main types, including T-cell mediated rejection
(TMR) and antibody-mediated rejection (AMR) [13]. Given the dearth of living or cadaveric donors, routine clinical follow-up, assessment, and functionality evaluation of the
kidney transplant is crucial to minimize the chance of kidney damage [14]. Chapter II will
provide a comprehensive survey about AR diagnosis. This will be followed by Chapter III,
which will discuss the developed AI-based CAD system for early and precise diagnosis of
AR.
In addition, RC is the 10th most prevalent cancer among men and women. It is
a heterogeneous disease in which the renal cells become malignant (cancerous) and form
tumors called renal masses. These renal tumors, if not detected early and treated promptly,
will lead to mortality [15, 16]. For the past several decades, an increasing number of new
patients have been diagnosed with RC. In the year 2022, approximately 79,000 new cases
are expected to be diagnosed with RC in the United States, and 14,000 patients are expected to die from RC in that same time period [15]. Roughly two thirds of the time,
RC is diagnosed before it has metastasized, in which case the 5-year survival rate is 93%.
Once it has spread to the lymph nodes or the surrounding abdominal organs or tissues,
the 5-year survival rate falls to 72%. In the worst case of metastasis to distant parts of
the body, the 5-year survival rate falls to 15% [15]. Renal cell carcinomas (RCCs) are
the most common and aggressive malignant tumors (≈ 70%). The World Health Organization (WHO) states that most common RCC subtypes are clear cell RCC (ccRCC), and
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non-ccRCC including papillary RCC (paRCC) and chromophobe RCC (chrRCC), representing 70%, 15%, and 5% of all RCCs, respectively. These malignant tumors have
different grades (I-IV) which specify how aggressive the tumor is as well as different
stages (I-IV), which help specifying the size of the tumor and how far it has spread to
veins, lymph nodes, or other abdominal structures (i.e. metastasis). This RCC taxonomy
is crucial for handling different prognosis [15, 17]. In addition, angiomyolipoma (AML)
and oncocytoma (ONC) are benign renal tumors that can be easily misclassified as RCC
(≈ 15% - 20%) using traditional diagnostic methods such as physical examination and/or
visual qualifications, particularly if these AML are fat-poor tumors, which might lead to
unneeded surgeries [18]. Therefore, early and accurate diagnosis of RC is essential to provide the appropriate timely intervention and management plans. Chapter IV will provide
a comprehensive survey about RC diagnosis. This will be followed by Chapter V that will
discuss the developed AI-based CAD system for early and precise diagnosis of RC.
This dissertation is given in six chapters with their scopes summarized below:
Chapter I: This chapter gives an overview about different ML and DL techniques that
had been utilized to build AI-based CAD systems to early diagnose different diseases
that might affect many organs in human body with the focus on two of the most critical
kidney diseases. Namely; AR and RC are discussed with their fast facts, consequences,
and different types.
Chapter II: This chapter provides a comprehensive survey about most of the related
studies in the literature that have used ML and/or DL to develop an AI-based CAD system to early diagnose AR using magnetic resonance images (MRIs). It starts with the
basic anatomy of the kidney, the gives fast facts about the AR post transplantation and the
traditional diagnostic techniques of AR.
Chapter III: This chapter details the developed AI-based CAD system with its novel4

ties and contributions for early and accurate diagnosis of AR using multimodal MRIs and
clinical biomarkers. The developed AI-based CAD system performs kidney segmentation, followed by the estimation of best hand-crafted discriminating functional markers
from multimodal MRIs. These markers are then integrated with their associated clinical
biomarkers. The integrated biomarkers were then used to train and test a deep learningbased classifier; namely, SAEs to differentiate non-rejection (NR) from AR. Then, the
diagnostic performance of developed AI-based CAD system is evaluated and discussed to
draw a final take-home message.
Chapter IV: This chapter provides a comprehensive survey on most of the related studies
in the literature from the last decade that have utilized ML and/or DL along with Radiomic
markers extracted from multi-phasic contrast enhanced computed tomography (CE-CT)
images to build an AI-based CAD system for early diagnosis of RC, including identifying
the malignancy status, subtyping, grading, and staging. It starts with fast facts about
RC, then discusses briefly the traditional diagnostic techniques of RC, different Radiomic
markers, and possible treatment plans.
Chapter V: This chapter introduces a novel AI-based CAD system to early and precisely diagnose RC. The developed AI-based CAD system extracts the best discriminating
hand-crafted morphological, textural, and functional markers from CE-CT images. These
markers are then integrated and used to train and test a two-stage MLP-ANN classifier to
differentiate malignant from benign RCC renal tumors and identify the malignancy subtype. Then, the diagnostic performance of developed AI-based CAD system is evaluated
and discussed to draw a final conclusion.
Chapter VI: This chapter concludes the work that has been done in this dissertation,
highlights the main contributions and obtained results, and spots the lights on possible
future avenues to be handled.
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Main contributions of this dissertation can be summarized as follows:

• A new AI-based CAD system was developed to precisely diagnose AR post kidney
transplantation at an early stage. The developed system was named Renal-CAD and
encompasses the following contributions:
– Extraction of DW-MR image markers, namely: voxel-wise apparent diffusion
coefficients (ADCs) are calculated from the segmented kidneys at 11 different low and high b-values and then mapped to their cumulative distribution
functions (CDFs) for better representation.
– Extraction of BOLD-MR image markers, namely: the transverse relaxation
rate (R2*) values from the segmented kidneys at four different echotimes and
then R2* curves were constructed for better representation.
– Integrating the extracted multimodal MR image markers with the associated
clinical biomarkers serum creatinine (SCr) and creatinine clearance (CrCl).
These integrated biomarkers are then fed to the developed DL classification
model built on SAEs to diagnose the kidney transplant as NR or AR.
• A new AI-based CAD system for precise diagnosis of RC at an early stage was developed. The developed system was named RC-CAD and incorporates the following
major contributions:
– Integrating the morphological features the best describe the surface complexity
of a given renal tumor, with first and second order appearance-based features
that can capture the texture heterogeneity of a given renal tumor, and with the
functional features by constructing wash-in/wash-out slopes to quantify the
enhancement variations across different CE-CT phases.
6

– Modeling a two-stage MLP-ANN classifier using the aforementioned integrated features to diagnose the renal tumor as benign or malignant and identify
the malignancy subtype.
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CHAPTER II
KIDNEY DIAGNOSIS SURVEY

A.

Background on Acute Rejection

Kidneys are important organs that are acting as a filtration system in human bodies. Kidneys are able to keep nutrients like salts, sugar, and protein, while at the same
time they are responsible for removing waste products, removing excess fluids, balancing
minerals and chemicals, producing red blood cells, controlling blood pressure, and maintaining healthy bones [19]. Although most humans are born with two kidneys, one normally functioning kidney should be enough to live in a healthy manner. However, several
diseases might rise up and badly affect the kidneys, which hinder them from performing
their functions in a normal way. As shown in Figure 1, the kidney is bean shaped and is
composed of an outer ”shell” known as renal cortex; an inner layer known as medulla; and
a hollow area known as renal pelvis, where the urine is collected [20]. Inside the cortex
and medulla are the filtration units known as the nephrons (see Figure 1), which are then
made up of smaller subunits such as the glomerulus, vasa recta, and loop of Henle [20].
Since the kidneys must filtrate the blood, they must be connected to veins and arteries. The
kidneys are connected to the renal artier and vein which are connected to the iliac artery
and vein, respectively. It is clear that kidney has a very complex structure and is associated
with many diseases and medical conditions that might arise (e.g., Chronic kidney disease
(CKD)).
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FIGURE 1: Anatomy of the kidney
CKD is the 10th leading cause of mortality in the United States. Approximately,
15% that is 37 million of the population in the USA suffer from CKD with more than
780,000 patients diagnosed with end-stage renal disease (ESRD) [8]. Over $114 billion is
spent annually on diagnosis and treatment of CKD or ESRD [21]. Although renal transplantation provides the best outcome for ESRD patients, only 17,500 renal transplants are
performed in the USA each year due to the paucity of donor organs [10, 11]. In addition, during the first 5 years after transplantation, there is a 15% - 27% chance that the
immune system will reject the foreign organ, leading to acute rejection (AR) post kidney
transplantation [12]. AR is considered the leading cause of kidney transplant dysfunction
with two main types including T-cell mediated rejection (TMR) and antibody-mediated
rejection (AMR) [13]. AR of renal allografts has to be detected and treated promptly at an
early stage, to minimize permanent damage and failure of the transplanted kidney [10, 11].
Given the dearth of living or cadaveric donors, routine clinical follow-up, assessment, and
functionality evaluation of the renal allograft post-transplantation is crucial to minimize
9

allograft loss [14]. The diagnostic technique that is currently recommended by the National Kidney Foundation (NKF) for assessing renal allograft function is the glomerular
filtration rate (GFR). The GFR has low sensitivity and is a late indicator for renal allograft dysfunction as major/noticeable changes can only be observed after>60% of renal
allograft function is lost [22]. Renal biopsy, the gold standard, is used as a conclusive AR
diagnostic tool. However, it cannot be used as a screening or early detection tool due to
high invasiveness, high cost, long time for recovery/report, and associated adverse events
(infection, bleeding, etc.). Therefore, there is a significant unmet clinical need for a noninvasive diagnostic tool that can provide a precise and early identification of AR renal
allograft. In this chapter, we will discuss most of the related studies that have utilized
magnetic resonance imaging (MRI) to early diagnosis AR post kidney transplantation.

B.

Related Work

Dynamic contrast enhanced (DCE) MRI provides, high contrast, low signal-tonoise (SNR) ratio, and thus; provide sufficient anatomical and functional information
about the kidney [23–26]. Therefore, it had been investigated by researchers to develop
AI-based CAD systems for renal function assessment [24–33]. For example, Farag et
al. [27] developed an AI-based CAD system for early diagnosis of AR. Their CAD was
evaluated on 30 patients and classified kidney status of each patient using four indexes:
the peak signal intensity, the time-to-peak, the wash-in slope, and the wash-out slope,
calculated from the MRI signal for the kidney cortex. Bayesian classifier was used and
their CAD classified 13 out 15 and 15 out of 15 correctly for both training and testing, respectively. They extended their studies in [34] by constructing perfusion curves from the
whole kidney rather than only the cortex. On a larger cohort of 100 patients, their modified
CAD achieved a 94% accuracy using Bayesian classifier as well. Zikic et al. [25] eval-
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uated kidney kinetic parameters as the contrast-invariant similarity measure. However,
the evaluation of perfusion parameters (plasma volume and tubular flow) was performed
visually by trained physicians for 10 data sets of healthy volunteers. De Senneville et
al. [26] evaluated renal function for both native and transplanted kidneys. The renal cortex
was segmented manually and the GFR was estimated with Patlak-Rutland tracer kinetic
model. The study demonstrated a significant uncertainty reduction on the computed GFR
for native kidneys (10 healthy volunteers), but not the transplanted ones (10 transplant
patients). Aslan et al. [28] developed an automated CAD system to classify NR from
AR renal allografts using DCE-MRI. Following kidney segmentation, three classification
methods (least square support vector machines (LS-SVMs), Mahalanobis distance, and
the Euclidean distance) were compared to assess transplant status based on medullary perfusion curves. On a cohort of 55 clinical data sets, they a achieved a diagnostic accuracy,
sensitivity, and specificity of 84%, 75%, and 96%, respectively using the Mahalanobis
distance-based classifier. Zöllner et al. [24] extracted functional parameters using k-means
clustering. This system was tested on only 4 DCE-MRI datasets and the evaluation of kidney regions was assessed qualitatively according their mean signal intensity time courses.
Wentland et al. [29] utilized MRI-based intrarenal perfusion measurement to differentiate between NR, ATN, and AR on a cohort of 24 renal allografts. The study concluded
that the cortical and medullary blood flow is significantly reduced in grafts experiencing
AR, as compared with NR. Additionally, AR patients demonstrated medullary blood flow
reduction as compared with ATN patients. Abou El-Ghar et al. [30] explored the feasibility of DCE-MRIevaluated the functionality on 55 patients using the mean medullary
intensity a achieved sensitivity, specificity and accuracy of 75%, 96% and 84%, respectively, to separate NR from AR. Yamamoto et al. [31] utilized DCE-MRI to identify the
cause of acute graft dysfunction. Their study included 60 patients (NR = 31 and AR =
29). Their study employed a multi-compartmental tracer kinetic model to estimate the
GFR and mean transit time (MTT) at different compartments of the kidney. The study
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document differences in the fractional MTT values between NR and AR groups; however,
substantial overlaps among these groups and with normal kidneys were observed. Khalifa et al. [32] included 26 data sets, and a K-nearest neighbor classifier was used. Their
CAD system achieved a 92.31% correct classification using the time-to-peak and wash-out
slope empirical parameters that are estimated from the agent kidney kinetic curves. Their
framework was extended in [33] by using four augmented empirical parameters (peak intensity value, time-to-peak, up-slope and average plateau). Unlike [32], the parameters
were derived from the cortex rather than from the whole kidney and the system was tested
on 50 patients, and the overall diagnostic accuracy increased to 96%
Although AI-based CAD systems that utilized DCE-MRI have shown promising
results to assess the status of the renal allograft post-transplantation, the use contrast agents
may adversely affect the kidney and cause nephrogenic systemic fibrosis [35] when GFR
< 30 ml/min/1.73m2 . Thus, medical centers are reluctant to use DCE-MRI anymore in
patients with renal disease [13, 23, 35]. To overcome these limitations, researchers started
to investigate other modalities of MRIs. Diffusion-weighted MRI (DW-MRI) [36–41] and
blood oxygen level-dependent MRI (BOLD-MRI) [37, 42–49] have been widely used to
assess the status of the renal allograft post-transplantation at an early stage. These modalities provide both anatomical and functional information about the kidney while avoiding
the use of contrast agents. DW-MRI enables non-invasive, in-vivo mapping of the diffusion of water molecules in tissues. These in-vivo diffusion maps are known as apparent
diffusion coefficients (ADC) and can be obtained at different magnetic field strengths and
duration (b-value) [50]. Thus, they can reveal the functional status of the kidney (normal
or diseased) [13, 37]. While BOLD-MRI estimates the amount of oxygen diffused blood
(i.e. oxygen bioavailability) in the kidney to determine whether it is functioning properly.
Specifically, the amount of deoxyhemoglobin is measured by the apparent relaxation rate
(R2*) parameter [13, 37].
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Eisenberger et al. [41] assessed the function of kidney transplants using DW-MRIs.
Scans were collected at 10 different b-values (0, 10, 20, 50, 100, 180, 300, 420, 550, 700
s/mm2 ) for 15 patients with renal allografts (NR = 10, AR = 4, acute tubular necrosis
(ATN) = 1). After placing manual ROIs, means and standard deviations of the ADC values were estimated from all b-values. The NR renal allografts demonstrated significantly
higher ADC values in both cortex and the medulla compared to AR and ATN patients.
The ADCs were directly correlated with the creatinine levels. Hueper et al. [36] investigated the role of DW-MRIs in assessing the function of transplanted kidneys. Their study
consisted of 64 participants (NR = 33 patients, AR = 31 patients) and DW-MRIs were
acquired at b0 and b600 s/mm2 . Manual ROIs were placed in the medulla and cortex of
the allograft, and the associated ADCs were estimated from these ROIs. AR allografts
had a significant decrease in ADC values, which conformed with biopsy reports. A total
of 69 renal allograft patients (non-rejection (NR) = 43, AR= 26) were enrolled in a study
conducted by Xu et al. [51]. Manual regions of interest (ROI) were placed on renal cortex and medulla and the ADCs were estimated. Renal allografts with AR demonstrated
lower ADCs than NR kidneys. The b800 had the highest sensitivity and specificity of all
measured b-values. Palmucci et al. [52] evaluated functionality of 21 transplanted kidneys
by comparing the estimated ADCs and true diffusion (TD) with renal function indices.
Patients were divided into three groups by their CrCl values. The cortical ADC and TD
were evaluated in a user-defined ROI of the transplanted kidney for the three groups. A
moderate positive correlation between the CrCl and both the ADC and TD, as well as no
difference between the ADC and TD values for the adjacent groups, has been found. The
subsequent extension [53] of these evaluations to 35 patients revealed a slightly smaller
positive correlation than the previously reported one [52]. However, acute rejection responses after transplantation could not be detected. Abou-El-Ghar et al. [38] conducted
a study to assess renal transplants function. Their study included 70 renal allograft patients. Using only two b-values of 0 and 800 s/mm2 , DW-MRI scans were conducted for
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21 patients with acute graft impairment (group 1) and 49 normal renal allografts (group
2). A user-defined ROI was placed in the middle portion of the kidney in a selected crosssection, and a pixie-wise ADCs were calculated. Their study revealed that group 1 had
significantly higher ADC values than group 2. Katarzyna et al. [54] investigated possible
relations between the diffusion parameters and selected laboratory results in the early stage
after kidney transplantation. The measurements were conducted in kidneys over multiple
user-defined ROIs at b-values of 600 and 1000 s/mm2 only. According to the relative
variability in the results and SNR, the optimum ADC value in the renal cortex was at b1000
s/mm2 with a strong dependency between the ADC measured at the same b-value and the
estimated GFR. Kaul et al. [39] evaluated the allograft function using the ADC values of
cortex and medulla. There were a significant reduction in ADC values of the medulla compared to the cortex in normally functioning donor and transplanted kidneys. They reported
that in case of AR, the ADC values decreased in the cortex and medulla. Remarkably, they
found that when the patients recovered from the AR using anti-rejection treatments, these
values increased significantly. Thus, this method can be used in therapy follow-up of AR
patients. Park et. al. [55] investigated the potential of DW-MRI in early detection of allograft dysfunction. 24 patients with early dysfunction and 10 with normal transplants were
enrolled in the study. The medullary and the cortical ADC values were calculated for the
patients. They found a moderate correlation between cortical or medullary ADC values
and estimated GFR. Moreover, the ADC values were higher in normal allografts than the
AR patients. Steiger et. al. [56] investigated the utilization of DW-MRI to classify kidney allograft biopsies by the seriousness of its pathological conditions. Renal DW-MRI
and biopsy were performed on 40 kidney recipients. The patients were divided by biopsy
results to one group of 15 patients with normal or simple pathological conditions and to
a second group of 25 patients with sever conditions. Classification based on the ADC
resulted in a sensitivity of 84.0% and specificity of 73.3%. When ADC was combined
with intravoxel incoherent motion parameter, an accuracy of 80% was achieved. Xie et.
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al. [57] investigated the ability of DW-MRI to detect the difference in function of renal
allografts. The study included 40 kidney recipients who were assigned to three groups
based on their eGFR with a unit of ml/min/1.73m2 . Groups 1, 2, and 3 had 16, 16, and 8
subjects with eGFR ≥ 60, 60 > eGFR ≥ 30, eGFR < 30, respectively. Also, 18 volunteers
who had eGFR ≥ 60 were added as group 4. Cortical total ADC of group1 was higher
than the group3. Also, total ADC and F p had positive correlation with the eGFR. Their
ROC analysis achieved 97.1% sensitivity and 66.7% specificity based on F p values.
In addition to diffusion studies, BOLD-MRI has been used by researchers to quantify renal allograft function by estimating the transverse relaxation rate R2*, which correlates with the relative proportion of deoxy- to oxyhemoglobin. Djamali et al. [44] assessed early-stage renal allograft dysfunction (the first four months post-transplantation)
using BOLD-MRI. In their study 23 renal allografts (NR = 5, AR = 13, ATN = 5). After
manual placements of cortical and medullary ROIs, cortical and medullary R2* were estimated. Their study reported that AR allografts had the lowest medullary R2* values as
well as the lowest medullary to cortical R2* ratios. Han et al. [42] explored the potential
of BOLD-MRI in demonstrating significant differences between normal and dysfunctional
renal allografts. A total of 110 patients (NR = 82, AR = 21, ATN = 7) who underwent
renal transplants were enrolled in their study. After manual placement of ROIs in cortices and medullas, mean cortical and medullary R2* values were estimated. Their study
demonstrated higher cortical and medullary R2* values in ATN group compared to both
AR and NR groups. The NR group had higher cortical R2* values than the AR group. No
correlations were found between R2* values and the creatinine level. Sadowski et al. [43]
conducted a study on 20 renal allografts (NR = 6, AR = 8, ATN = 6) using BOLD-MRIs.
Their study demonstrated lower medullary R2* values in AR patients compared to NR
and ATN patients. Xiao et al. [58] conducted a study to differentiate between AR and NR
kidneys post-transplantation using BOLD-MRIs. Their study included a total of 122 pa-
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tients (AR = 21, NR = 72, and 20 normal functioning kidneys). After placing 2D manual
ROIs, they estimated the R2* values for all participants. They reported significantly lower
medullary and cortical R2* values in AR than other normal groups. Mendes et al. [59]
investigated the potential power of BOLD-MRI to assess renal allograft post transplantation. Their study included 19 patients (AR = 4, ATN = 10, and other dysfunction = 5).
Using 2D ROIs, they estimated the R2* values to differentiate between different groups of
patients. Although they failed to find significant differences in cortical R2* values, they
found that the medullary R2* values were significantly higher in the AR group.
Studies that utilized both DW-MRI and BOLD-MRI in assessing renal allografts
post-transplantation have been performed [37, 60]. Vermathen et al. [60] followed up renal
allograft patients for 3-years post transplantation. Nine renal allografts were scanned twice
using both DW- and BOLD-MRIs to determine the changes in functional parameters (i.e.,
ADC and R2*) as an indication of the allograft rejection. They reported only small and
non-significant changes for NR allografts. ADC values were reduced significantly and
R2* values were higher in the second scan for AR allografts. A study by Liu et al. [37]
included 50 patients with renal transplants (NR = 35 AR = 10, and ATN = 5). Lower ADC
values were reported for AR compared to NR. Medullary R2* values were significantly
higher for ATN group compared to NR and AR groups.

C.

Discussion and Conclusions

Early detection of AR can help physicians with early intervention with appropriate treatment and thus prolong the renal graft function and improve patient outcomes.
Generally, there are multiple types of AR, and the selection of the appropriate treatment
depends on the rejection type. For example, acute cellular rejection is treated with a high
dose of corticosteroids, administrated intravenously as the first line treatment [61, 62].
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The most popular regimen is the administration of methylprednisolone for three successive days [61]. In the case of persistent kidney deficiency with the steroid and/or antithymocyte globulin or the presence of a new defect in renal function after treatment of AR,
another biopsy is recommended to discover additional causes of renal dysfunction. Tcell depleting antibodies are suggested for aggressive vascular cellular rejection and AR
episodes that do not respond to steroid treatments [63]. On the other hand, if antibody
mediated rejection is the resulting diagnosis, the following alternatives are suggested for
treatment: plasmapheresis, immunoadsorption, intravenous immunoglobulin, or monoclonal antibodies [64].
DCE-MRI had been efficient imaging modality to assess the status of the renal
allograft post-transplantation by estimating perfusion parameters. However, medical centers are reluctant to use DCE-MRI anymore in patients with renal disease [13, 23, 35]
as the contrast agent might adversely affect the kidney [35], especially when GFR < 30
ml/min/1.73m2 . DW-MRI and BOLD-MRI have been used by researcher as good replacement that is safer and suitable for all kind of patients regardless the value of GFR.
It is worth mentioning that most of the clinical research estimates the ADC at a few select b-values [36–39, 51, 54–57, 65], typically one of the lower b-values and one of the
higher b-values along with the baseline (b0). Perfusion is measurable at low b-values
≤ 200 s/mm2 [66, 67], while the high b-values account for the water diffusion [66–69].
Most of these studies agreed on that AR patients usually demonstrates reduced values of
ADCs. On the other hand, contradictions were found in the values of R2* to be higher
or lower in AR patients. At the end, these studies suggested that DW-MRIs and BOLDMRIs are valuable imaging tools to be used for the early evaluation of AR post kidney
transplantation [37, 38, 42–44, 70, 71].
The related work studies, discussed in this Chapter, had several limitations that
need to be addressed: (1) most of the studies investigated only significant differences and
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correlations among different renal transplant groups, and (2) none of these studies investigated the integration of image markers from different MRI modalities with clinical
biomarkers to enhance the diagnostic performance, and (3) none of these studies investigated the power of deep learning (DL) to produce a comprehensive, AI-based CAD system
to identify AR at an early stage. To overcome these limitations, in the next Chapter III, a
novel fully automated AI-based CAD system, named Renal-CAD, is developed to provide
an early and precise diagnosis of AR post kidney transplantation.
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CHAPTER III
KIDNEY REJECTION COMPUTER-AIDED DIAGNOSIS

A.

Materials

Forty seven patients who underwent renal transplantation were enrolled in this
study after providing consent. DW-MRI scans (n = 47 patients), BOLD-MRI scans (n =
30 patients), and renal biopsies (n = 47, M = 31, F = 16, age = 35 ± 16.13 years, age
range = 12–65 years) were obtained (June 2016 to June 2019) from two geographically
diverse countries (USA and Egypt). For the DW-MRI and biopsy data, two groups were
identified: NR group (30 patients) and AR group (17 patients). BOLD-MRI data included
20 NR patients and 10 AR patients. Kidney function for all patients participating in this
study, as a part of post-transplantation routine medical care, were assessed with their laboratory values, namely; creatinine clearance (CrCl) and serum creatinine (SCr). The NR
group (30 patients) had an average SCr value of 1.20 ± 0.36 mg/dl and CrCl value of 74.83
± 26.26 ml/min. The AR group (17 patients) had a mean SCr value of 1.63 ± 0.57 mg/dl
and CrCl value of 54.05 ± 22.28 ml/min. Renal biopsies and coronal MRI data were acquired within 48 hours of each other. The biopsy results were used as the ground truth for
comparison with the classification algorithm. The 47 DW-MRI scans (30 in Egypt and 17
in the USA) were acquired using two similar 3T Ingenia MRI scanners (Philips Medical
Systems, Best, The Netherlands) using a body coil and a gradient single-shot spin-echo
echoplanar sequence. However, data acquisition protocols were slightly different and are
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summarized in Table 1. For both DW-MRI acquisition protocols, water signals were acquired at different b-values of b0 , b50 , and b100 –b1000 s/mm2 at 100 increments, see Fig. 2.
Thirty BOLD-MRI scans were acquired in Egypt using the same 3T scanner; TR: 140 ms,
TE: 2 ms, Flip angle: 25◦ , Bandwidth: 150 kHz, slice size: 384 × 384, number of signals
acquired: 1, FOV: 14.4 cm, thickness: 6.0 mm. For each subject, the middle/largest coronal image was selected and obtained at five different echo-times (TE = 2, 7, 12, 17, and
22 ms), see Fig. 2. Both biopsy reports and MRI scans were included in the final analysis
and were examined by two clinicians, a radiologist and a nephrologist.

FIGURE 2: Data collection process demonstration for transplanted kidneys. DW-MRI
data are collected at 11-different gradient field strengths and duration (b-values) of (b0,
b50, b100, ..., b1000 s/mm2 ), while BOLD-MRI data are collected at 5-different TEs (2,
7, 12, 17, 22 ms).
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TABLE 1: Summary of the DW-MRI acquisition protocols of the data collected in USA
and Egypt. Note that TR/TE: repetition time/echo time, SZ: slice size, STH: slice thickness, IG: intersection gap, FOV: field of view, NCS: number of cross-sections.
Acquisition Protocol Metric
TR/TE

SZ (pixels)

STH (mm)

IG (mm)

FOV (cm)

NCS

Egypt (30)

4400/82

176×176

4

0

22

24

USA (17)

8000/93.7

256×256

4

0

36

38

B.

Methods

In this chapter, a novel fully automated AI-based computer-aided diagnostic system, named Renal-CAD (Fig. 15), is developed to provide a precise diagnosis of AR
post kidney transplantation at an early stage. The developed Renal-CAD system performs
the following major steps: (1) auto-segmentation of the renal allograft from surrounding
tissues from DW-MRI and BOLD-MRI, (2) extraction of multimodal MR image markers, namely: voxel-wise apparent diffusion coefficients (ADCs) are calculated from DWMRIs at 11 different low and high b-values and then represented as cumulative distribution
functions (CDFs) and the transverse relaxation rate (R2*) values are estimated from the
BOLD-MRIs at different echotimes and then R2* curves were constructed for better representation, (3) integration of multimodal MR image markers with the associated clinical
biomarkers, serum creatinine (SCr) and creatinine clearance (CrCl), and (4) diagnosing
renal allograft status as nonrejection (NR) or AR by utilizing these integrated biomarkers and the developed deep learning classification model built on stacked auto-encoders
(SAEs). Details of the developed Renal-CAD are discussed below.
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FIGURE 3: The proposed Renal-CAD system for early diagnosis of acute renal transplant
rejection (AR). The input diffusion-weighted (DW) and blood oxygen level-dependent
(BOLD) MRI data acquired at 11-different b-values and 5-different echo-times are first
segmented. Then, the DW-MR image markers (cumulative distribution function (CDF) of
the voxel-wise apparent diffusion coefficients (ADCs)) and the BOLD-MR image markers
(mean R2* curve) are constructed. These image markers are then integrated with clinical
biomarkers (creatinine clearance (CrCl) and serum creatinine (SCr)) and are fed into a
stacked auto-encoder (SAE) with a softmax classifier to obtain the final diagnosis as AR
or non-rejection (NR).
1.

Kidney Segmentation

Providing a fully-automated and precise segmentation of the renal allograft is a
key step in the Renal-CAD system. Precise extraction of imaging features for accurate
final diagnosis requires high segmentation accuracy. To improve segmentation accuracy,
data preprocessing was performed prior to applying the previously developed segmenta-
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FIGURE 4: Block diagram illustrating the kidney segmentation approach’s steps. The raw
DW- and BOLD-MRI data are first pre-processed to suppress noise and motion effects.
Then, a joint Markov-Gibbs random field (MGRF) image model that accounts for the
shape, intensity, and spatial features is employed. Finally, a level-set segmentation guided
by the MGRF model is applied to get the final segmented kidney.
tion approach [72], see Fig. 16. Briefly, histogram equalization was first applied on the
bias corrected [73] MR images to suppress noise effects and image inconsistencies. Then,
a nonrigid registration using B-splines approach [74] was employed to handle kidney motion and to reduce MRI anatomical variability among different patients to improve segmentation accuracy. Subsequently, renal segmentation based on the level-sets method [72] was
performed. To enhance kidney segmentation accuracy, a joint Markov-Gibbs random field
(MGRF) image model that combines three different components: shape, grey level, and
spatial MRI features was employed. Renal segmentation approach accuracy was evaluated
on all DW- and BOLD-MRIs for a more precise estimation of the discriminatory features.
Two examples for the segmentation approach’s results for both DW- and BOLD-MRIs are
shown in Figs. 5 and 6, respectively. Details of this approach has been described in the
published work [72].
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FIGURE 5: Segmentation results example for a DW-MRI subject. The upper raw shows
different DW-MRI coronal cross-sections raw data, while the lower raw shows the corresponding segmentation results with red edges.

FIGURE 6: Segmentation results example for a BOLD-MRI subject. The upper raw shows
different BOLD-MRI coronal cross-sections raw data at different echo times (from left to
right: 2, 7, 12, 17, and 22 ms), while the lower raw shows the corresponding segmentation
results with red edges.
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2.

Feature Extraction

Diffusion Weighted Imaging Markers: The significant advantages of DW-MRI is highlighted by its ability to quantify local characteristics of blood diffusion and to interrelate
them with the transplant status, due to DW-MRI’s ability to measure the unique characteristics of inner spatial water behavior in the soft tissue (e.g., kidney). This behavior is
quantified by apparent diffusion coefficients (ADCs) [37, 40, 55], which can be utilized
to evaluate the kidney transplant status. Following the accurate segmentation of the kidney, the DW-MR image-markers (i.e. voxel-wise ADCs) are estimated precisely using the
following equation [50, 75] as:
ADCvx =

ln g0:vx − ln gb:vx
b

(1)

vx : A voxel with its 3D Cartesian location (x, y, z).
g0 : T2-weighted signal intensity obtained at b = 0.
gb : Diffusion-weighted signal intensity obtained at the given b-value.
The voxel-wise ADCs were estimated at the 11-different b-values to be used as discriminatory features to assess kidney transplant. However, using such voxel-wise ADCs as
discriminatory features has the following limitations: (1) varying input data size that might
lead to data truncation and/or zero padding for smaller and/or larger kidney volumes, respectively and (2) considerable training and classification time is needed, especially, in the
case of large data volumes. In order to overcome these limitations, these voxel-wise ADCs
were characterized at the 11 different b-values, using the cumulative distribution functions
(CDFs) of the ADCs. To construct such CDFs, the minimum and maximum ADCs were
calculated for all input datasets. Then, CDFs of the voxel-wise ADCs were constructed at
the 11-different b-values (100 steps for each CDF) resulting in a DW-MR image markers
(Dmrks ) vector of size 1100 × 1. Please see Fig. 7.
25

FIGURE 7: Demonstration of DW-MRI features construction procedure. First, the apparent diffusion coefficients (ADCs) are estimated from the segmented kidneys at 11different b-values. Then, probability distribution functions (PDFs) and cumulative distribution functions (CDFs) are constructed consequently from the estimated ADCs at all
b-values.
BOLD-MR Imaging Markers: BOLD-MRI estimates the amount of the renal allograft
content of deoxygenated hemoglobin (R2*). By measuring T2* (i.e., the amount of oxygenated hemoglobin [49]) in the allograft, one can calculate the R2* by taking the reciprocal of T2*. The mean R2* values were estimated from the delineated allograft using four
different TE (7, 12, 17, 22 ms) resulting in a 4 × 1 vector of mean R2* values (Fig. 8). This
vector was used as the combined discriminatory BOLD-MR image-markers (Bmrks ) to assess renal allograft status. The BOLD-MRI data acquired at 2 ms was used as the baseline.
The pixel-wise T2* and R2* maps can be estimated using the following equations [48]:
T2∗px =

t0 − t
ln S It:px − ln S It0 :px

(2)

1
T2∗px

(3)

R2∗px =
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FIGURE 8: Demonstrating the procedure of constructing BOLD-MRI features, where the
mean T2* values are estimated from the segmented allograft at 4-different echo-times (TE
= 7, 12, 17, 22 ms). Then, the mean R2* values are estimated by taking the reciprocal of
the estimated T2* values.
px: a pixel with its 2D Cartesian location (x, y).
SIt : signal intensity obtained at TE = t and extracted from the segmented image.
SIt0 : signal intensity obtained at the baseline TE = 2 ms and extracted from the segmented
image.
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3.

Deep Learning-based Stacked Autoencoders

Deep learning is a machine learning approach that is widely used in many applications, including in the medical domain (e.g., detection, diagnosis, prediction, etc.) for specific diseases. An autoencoder (AE) is an artificial neural network (ANN) that employs an
unsupervised deep learning/training approach followed by a supervised backpropagationbased refinement algorithm to provide a better classification performance [4, 5, 76]. The
main structure of an AE, shown in Fig. 9, can be basically defined as three main types
of layers: an input layer, a hidden layer, and an output layer. The AE training procedure
can be classified into encoding and decoding processes. In the encoding process, the input
data is mapped into a hidden representation through the hidden layer. In the decoding process, the input data are reconstructed from the hidden-layer representation. Both encoding
and decoding processes are primarily used to learn an approximation to the identity funcb (i.e., decoding process output) is almost
tion, which implies that the reconstructed input X
identical to the input X, see Fig. 9. The main purpose of this identity function is to force
the AE to learn a compressed representation of the input, especially when the number of
hidden nodes is less than the input size. Conversely, the AE is forced to reconstruct the
input back given only the hidden features/activations.
Given the unlabeled training input dataset {Xn : n = 1 . . . N}, such that each Xn ∈
Rm , Hn ∈ Rk represents the hidden layer’s features/activations resulting from the encoding
process of the input vector Xn , this encoding process can be described by the following
equation:

Hn = fe (We Xn + Be ) ,

(4)

where fe represents the encoder activation function, which in this study is a sigmoid func-
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FIGURE 9: A demonstrative figure for the basic structure of the autoencoder (AE), where
each AE consists of an input layer, a hidden layer, and an output layer. After training
each AE separately, AE1 is stacked with AE2 and a softmax classifier on the top of them
to obtain a stacked AE (SAE). Then, a backprobagation-refinement algorithm is used to
update the hidden weights of the SAE.
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tion, i.e. a differentiable, monotone scalar function with range (0, 1). We ∈ Rk×m and
Be ∈ Rk are the weight matrix and the bias vector of the encoder, which are randomly
initialized. Given the hidden layer’s features/activations Hn obtained from the aforementioned encoding process, the following equation describes the decoding process to obtain
b
the reconstructed input X:

bn = fd (Wd Hn + Bd ) ,
X

(5)

where fd represents the decoder function, while Wd and Bd are the weights and biases of the
decoder, respectively. The optimal set of hyper-parameters of the AE can be tuned based
on the compression/decompression reconstruction error minimization criteria as follows:
n

JAE (W, B) =

1 X b
XW:i − Xi
2n i=1

2

,

(6)

bW:i − Xi ∥2 represents the loss function that needs to be minimized, which in turn
where ∥X
will lead to the reduction of the reconstruction error JAE (W, B) at the end. To obtain
the final stacked AEs (SAEs) that will be used in the Renal-CAD system for the early
detection of AR, two autoencoders (AE1 and AE2 ) followed by a softmax classifier were
trained and stacked together, see Fig. 10. Algorithm summarizes building and optimizing
the SAE classification model.
Overfitting and Dropout Technique: Deep neural networks (DNNs) are known with
their complex structure, which makes them prone to overfitting. A DNN is overfitted when
it fails to generalize or provide a correct analysis/output given a new set of input data.
Overfitting typically occurs when the training set is not large enough. Dropout technique
is a proven methodology for its ability to reduce overfitting in the training phase [77,
78]. Using dropout technique, one can obtain various representations for the relationships
between the training data. Some of the hidden neurons can be randomly deactivated, while
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FIGURE 10: An illustrative figure showing the structure of the proposed SAE classifier. The feature vector uses the concatenation criteria to integrate diffusion markers with
BOLD markers and clinical biomarkers. This vector is used as the SAE’s input and processed through two hidden layers and a softmax classifier to get the final probability of
being an AR or NR renal allograft.
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Algorithm 1 Building, Stacking, and Optimizing The Developed SAE
1 Train the first autoencoder AE1 , separately, by using the input data X1 to obtain the
learned features/activations H1 .
2 Use the features/activations (H1 ) obtained from AE1 as an input to train the second
AE2 .
3 Use the features/activations (H2 ) obtained from the second AE2 as an input to train a
softmax classifier to compute the plausibility of being assigned to class 1 or 2.
4 Stack AE1 , AE2 , and the softmax classifier together to get your SAEs, and use a supervised backpropagation-based refinement algorithm to minimize the conventional error
in the SAEs and update the hidden weights.
5 Finally, fine tune the hyper-parameters by using a grid search criteria that minimizes the
cost function as an optimization metric to provide a better classification performance.
preserving their corresponding weights and biases, in each iteration during the training
phase. In the next iteration, these deactivated neurons could be re-activated and some other
different neurons might be deactivated. These permutating deactivation process leads to
reduction in the total number of the activated neurons and thus hinder the complex coadaptations between training data. In this chapter, the dropout technique was used to
suppress the overfitting effect by extracting meaningful features and to improve the final
diagnostic accuracy of the developed Renal-CAD system.

4.

Kidney Diagnosis by Integrating Diffusion, BOLD, and Clinical Biomarkers

To obtain an accurate assessment of the kidney transplant, the following different
sources of information were integrated: (i) the estimated Dmrks vector of size 1100×1 to
interrelate local blood diffusion characteristics with the transplant status; (ii) the estimated
Bmrks vector of size 4×1 to quantify the amount of the renal allograft content of deoxygenated hemoglobin and interrelating it with the transplant status; and (iii) the combined
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clinical biomarkers (SCr and CrCl) resulting in Cbmrks vector of size 2×1 to measure the
creatinine levels in both blood and urine, and thus; the filtration ability for renal transplant
assessment. These three sources of information were integrated using the concatenation
method resulting in an integrated biomarkers (Ibmrks ) vector of size 1106×1 that will be
used as the final discriminatory features between the AR and NR groups.
After obtaining the Ibmrks , a classification process based on using a leave-onesubject-out cross-validation (LOSOCV) approach was employed using SAEs to obtain
the final diagnosis. The Ibmrks of size 1106×1 were fed as an input vector to SAEs to build
the classification model. A grid search algorithm minimizing the cost function as an optimization metric was employed to find the optimal-set of hyper-parameters. The two-layer
SAEs with the first hidden layer (n = 9 nodes), second hidden layer (n = 3 nodes), output
softmax layer (n = 2 nodes), weight decay parameter = 0.0022, weight of sparsity penalty
term = 20, desired average activation of the hidden units = 0.2421, and dropout fraction =
0.5, provided the optimal diagnostic accuracy using LOSOCV approach and was selected
for the proposed Renal-CAD system (Fig. 10).

C.

Experimental Results

Two methods were used for train, test, and validation purposes. The first one is
known as K-fold (i.e., LOSOCV) and is depending on training the network with all data
while leaving only one subject outside for testing purpose. Then, in the next iteration,
the network was reinitialized, and the subject that was left in the previous iteration was
included back in the training data and the next subject was left outside for testing purpose.
This procedure was repeated by the number of the subjects (N = 30, Training Data =
29, Testing Data = 1) and the diagnostic results were reported. The second validation is
known as stratified 10-fold cross-validation in which 90% of the data were used for the
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training and 10% of the data were randomly selected and kept for testing. Then, in the next
iteration, the network was reinitialized and that 10% was included back in the training set
and another randomly selected 10% was kept for testing. This process was repeated for
10 times (N = 30, Training Data = 27, Testing Data = 3).
It is worth mentioning that stratification was assured in the 10-fold cross-validation
to help reduce both bias and variance. Stratification technique does not only allow for
randomization but also ensures that the training/testing spilt percentages of each class in
the entire data will be similar within each individual fold. In this case, NR = 20 subjects
(67%) and AR = 10 subjects (33%), stratification ensures that 67% of the training data
will be derived from NR subjects and 33% will be derived from AR subjects and the same
percentages will be maintained for the test data too.
Renal-CAD software is primarily implemented in Matlab (The MathWorks, Natick, Massachusetts), with time-critical subroutines developed in C using the Matlab Mex
API. Cross-validation experiments were performed on a Dell Precision workstation with
Intel Xeon eight-core CPU running at 2.1 GHz and 256 GiB RAM.
The developed Renal-CAD system with SAEs classifier was tested using the Ibmrks
constructed for the 30 datasets that had both DW- and BOLD-MRI scans based on the
LOSOCV approach. To demonstrate the effect of integrating Dmrks with Bmrks and Cbmrks
and highlight its advantages, six additional scenarios were performed and compared with
the Renal-CAD system using accuracy, sensitivity, and specificity as performance evaluation metrices, see Table 2. The first scenario (S 1 ) utilized the Dmrks alone on the 47
datasets along with the same SAEs classifier and the LOSOCV approach. The second
scenario (S 2 ) employed the Bmrks alone on the 30 datasets along with the same LOSOCV
approach. However, because the Bmrks are of smaller size (i.e. 4×30), SAEs were replaced
with a conventional multi-layer preceptron artificial neural network (MLP-ANN) classi-
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fier with two hidden layers (hl1 , n = 3 nodes and hl2 , n = 1 node). The third scenario
(S 3 ) used the Cbmrks alone on the 47 datasets along with the same LOSOCV approach.
However, because the Cbmrks are of smaller size (i.e. 2×47), the SAEs were replaced by
a linear discriminant analysis (LDA) classifier. The fourth scenario (S 4 ) integrated both
Dmrks with Bmrks resulting in DBmrks on the 30 datasets along with the same SAEs classifier
and the LOSOCV approach. The fifth scenario (S 5 ) integrated both Dmrks with Cmrks resulting in DCmrks on the 47 datasets along with the same SAEs classifier and the LOSOCV
approach. The sixth scenario (S 6 ) integrated both Bmrks with Cmrks resulting in BCmrks on
the 30 datasets along with the same LOSOCV approach. However, because the BCmrks
are of smaller size (i.e. 6×30), SAEs were replaced with a MLP-ANN classifier with two
hidden layers (hl1 , n = 5 nodes and hl2 , n = 1 node). Results in Table 2 suggests that the
utilization of the Ibmrks had a positive effect on the final diagnostic accuracy. This can be
justified in part by the different abilities of each individual marker (i.e. Dmrks , Bmrks , and
Cbmrks ) to evaluate renal allograft function, which are complementary to each other.
To ensure that the developed Renal-CAD system is not prone to overfitting (i.e.,
after using the dropout technique) and to validate the reproducibility and robustness of the
Renal-CAD system, a stratified 10-fold cross-validation approach was performed on the
same dataset (N = 30) using the same integrated biomarkers Ibmrks and the same SAEs with
its previously defined structure and hyper-parameters. Results are reported in Table 3 and
compared with the results obtained earlier using the LOSOCV approach in terms of accuracy, sensitivity, specificity, and area under the curve (AUC). In addition, the LOSOCV
experiment was repeated 100 times with different randomly selected network initialization to ensure that the Renal-CAD system would be able to produce consistent diagnostic
results. The Renal-CAD system produced the following diagnostic results: 91.65 ± 1.74
(% accuracy), 90.0 ± 0.0 (% sensitivity), and 92.5 ± 2.64 (% specificity). These validation
experiments demonstrated the reproducibility and robustness of the Renal-CAD system.
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TABLE 2: Diagnostic performance comparison between the proposed Renal-CAD system
using the integrated biomarkers (Ibmrks ) and six other scenarios S 1 , S 2 , S 3 , S 4 , S 5 , and S 6
using the individual DW-MR image markers (Dmrks ), BOLD-MR image markers (Bmrks ),
clinical biomarkers (Cbmrks ), integrated diffusion and BOLD markers DBmrks , integrated
diffusion and clinical biomarkers DCmrks , and integrated BOLD and clinical biomarkers
BCmrks respectively. Let Acc: accuracy, Sens: sensitivity, Spec: specificity, and AUC: area
under the curve.
Classification Performance (NR vs. AR)
S 1 (Dmrks )

S 2 (Bmrks )

S 3 (Cbmrks )

S 4 (DBmrks )

S 5 (DCmrks )

S 6 (BCmrks )

Renal-CAD(Imrks )

Acc%

80.9

86.7

70.2

90.0

87.2

90.0

93.3

Sens%

76.5

80.0

80.0

90.0

82.4

80.0

90.0

Spec%

83.3

90.0

52.9

90.0

90.0

95.0

95.0

AUC

0.84

0.84

0.71

0.90

0.88

0.88

0.92

TABLE 3: Diagnostic performance of the developed Renal-CAD system using the integrated biomarkers (Ibmrks ) using LOSOCV approach vs. 10-fold cross-validation approach.
Let Acc: accuracy, Sens: sensitivity, Spec: specificity, and AUC: area under the curve.
Classification Performance (NR vs. AR)
Acc% Sens% Spec%

AUC

Renal-CAD (LOSOCV)

93.3

90.0

95.0

92.0

Renal-CAD (10-fold)

86.7

80.0

90.0

0.88
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Statistical analysis was performed using R version 3.6. Differences in ADC or
R2* between groups (AR/NR) were analyzed using MANOVA. Statistical significance
was estimated from Pillai’s trace, converted into its approximately equivalent F statistic. MANOVA was performed using the individual imaging parameters by themselves,
combined imaging parameters, and also in combination with lab values (CrCl and SCr).
Follow up comparisons of ADC or R2* at each individual b-value or time point, respectively, were made using t-tests.
From Tables 4 and 5, renal allografts without AR had a slightly higher, albeit not
significantly, mean ADCs at individual b-values, particularly with higher gradients ≥ 200,
compared to AR. When all gradients were combined together, NR group had significantly
higher ADCs than the AR group. The AR renal allografts had a higher, but not significant, mean R2* at the different echo-times (i.e. lower T2* values, which means lower
amount of oxygen supply). Similarly, the combined R2* model did not reach significant
differences. Table 6 demonstrates the statistical significance between the two groups (AR
vs. NR) using the individual clinical biomarkers, all of the possible pair-wise multivariate
combinations, and the combination of the imaging modalities with the clinical biomarkers
(All). As reported in Table 6, the CrCl and SCr have shown statistically significant differences between the two groups (the NR group demonstrated higher CrCl values and lower
SCr values than the AR group). In addition, all possible pair-wise combinations and the
combined model (All) demonstrated statistical significance between the two groups.
The performance of the developed Renal-CAD system was evaluated by constructing the receiver operating characteristics (ROC) [79], see Fig. 11. Furthermore, the performance of Renal-CAD system was compared to the six scenarios (S 1 , S 2 , S 3 , S 4 , S 5 ,
and S 6 ) in terms of area under the curve (AUC). The Renal-CAD demonstrated the highest AUC of 0.92, as shown in Table 2 and Fig. 11. In addition, reproducibility and robustness of the Renal-CAD system was confirmed by comparing the performance of the
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TABLE 4: A comparison in terms of means and standard deviations (stds) of the ADC
maps at 11-individual b-values between the non-rejection (NR) group and the acute rejection (AR) group. Statistic is t with approximately 31 effective degrees of freedom in
univariate case, F with 11 degrees of freedom in the numerator and 35 in the denominator
in the multivariate case.
ADC Maps at Individual b-values: mean(std) ≈
b (s/mm2 )

50

100

200

b300

400

500

600

700

800

900

1000

Combined

NR(30)

4.0(0.66)

3.31(0.48)

2.86(0.31)

2.62(0.25)

2.48(0.20)

2.35(0.18)

2.25(0.15)

2.17(0.13)

2.09(0.12)

2.01(0.12)

1.94(0.11)

−−−−−

AR(17)

3.99(0.71)

3.37(0.48)

2.81(0.36)

2.53(0.32)

2.37(0.25)

2.26(0.23)

2.17(0.23)

2.07(0.22)

2.00(0.20)

1.93(0.19)

1.87(0.18)

−−−−−

Statistics

−0.016

0.368

−0.465

−1.00

−1.52

−1.40

−1.36

−1.62

−1.65

−1.61

−1.56

2.49

p-value

0.987

0.715

0.645

0.326

0.139

0.173

0.188

0.119

0.113

0.120

0.133

0.020

TABLE 5: A comparison in terms of means and standard deviations (std) of the R2* maps
at 4-individual echo-times between the non-rejection (NR) group and the acute rejection
(AR) group. Statistic is t with approximately 13 effective degrees of freedom in univariate
case, F with 4 degrees of freedom in the numerator and 25 in the denominator in the
multivariate case.
R2*/s Values at Individual Echo-times: mean(std) ≈
Echo-time

7 ms

12 ms

17 ms

22 ms

Combined

NR(20)

23.6(18.0)

19.9(5.8)

19.9(7.2)

19.4(4.7)

−−−−−

AR(10)

25.1(16.8)

20.3(9.3)

23.7(11.3)

23.3(10.3)

−−−−−

Statistics

0.244

0.149

0.974

1.14

1.95

p-value

0.810

0.884

0.348

0.277

0.133

Renal-CAD using a 10-fold cross-validation to the LOSOCV approach in terms of ROC
(Fig. 12) and AUC (Table 3).
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FIGURE 11: Receiver operating characteristics (ROC) curve for the proposed Renal-CAD
system vs. six other different scenarios, namely; S 1 , S 2 , S 3 , S 4 , S 5 , and S 6 using the
individual DW-MR image markers (Dmrks ), BOLD-MR image markers (Bmrks ), clinical
biomarkers (Cbmrks ), the combined DW- and BOLD-MR image markers (DBmrks ), the combined DW-MR image markers and clinical biomarkers (DCmrks ), and the combined BOLDMR image markers and clinical biomarkers (BCmrks ), respectively. The Renal-CAD area
under the curve (AUC) is almost approaching the unity, demonstrating the feasibility and
robustness of the developed system.
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FIGURE 12: Receiver operating characteristics (ROC) curve for the proposed Renal-CAD
system using the leave-one-subject-out cross-validation (LOSOCV) approach with an area
under the curve (AUC) of 0.92 vs. using the 10-fold cross-validation approach with an
AUC of 0.88. A reduction of only 0.04 in the AUC demonstrates the reproduciblity and
robustness of the developed system.

40

TABLE 6: A comparison in terms of means and standard deviations (stds) of the clinical
biomarkers (CrCl and SCr) between the non-rejection (NR) group and the acute rejection
(AR) group. Note: d.f. denotes degree of freedom with different values depending on the
combined variables.
Data

CrCl

SCr

Dmrks +Cmrks

Bmrks +Cmrks

Dmrks +Bmrks

All

NR

74.8(26.3)

1.2(0.4)

− − −−

− − −−

−−−−−

−−−−−

AR

54.1(22.3)

1.63(0.6)

− − −−

− − −−

−−−−−

−−−−−

Statistics

−2.88

2.81

2.51

3.78

3.00

3.57

d.f.

38.1

23.4

13/33

6/23

15/14

17/12

p-value

0.007

0.010

0.016

0.009

0.023

0.015

D.

Discussion and Conclusions

The classification results of the Renal-CAD system that integrated multi-modal
imaging markers and clinical biomarkers demonstrated high accuracy, sensitivity, and
specificity. These results demonstrated the feasibility and efficacy of the Renal-CAD
system to precisely and non-invasively identify renal allograft status at an early stage.
Classification results obtained using individual imaging modalities (DW-MRI or BOLDMRI) had lower accuracy, sensitivity, specificity, and area under the curve compared to the
Renal-CAD system. The estimated diffusion markers (Dmrks ) has the potential to interrelate local blood perfusion and water diffusion characteristics with the transplant status and
thus, provide a good discriminator between AR and NR renal transplants. Most of the clinical studies estimated the ADC values at two selected b-values. Usually, they select one
with a low gradient strength b-values < 200 to be able to measure blood perfusion [66, 67]
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and one with a high gradient strength > 200 to be able to measure water diffusion inside
the kidney [66–69]. This study utilized 11-different gradients to estimate both blood perfusion and water diffusion to enhance diagnostic accuracy. The obtained results are in line
with the findings of other clinical studies [36, 38–41, 51, 56, 57, 65] in that the NR renal
transplants demonstrated higher ADC values than AR transplants (b-value > 200).
The estimated BOLD-MRI markers (Bmrks ) can quantify the amount of the renal
allograft content of deoxygenated hemoglobin to interrelate with the transplant status.
There is no consensus regarding whether NR or AR has higher R2* values. Further, the
threshold R2* values to distinguish AR from NR are not known [43, 44, 49]. The findings
of this study suggest that AR renal allografts demonstrate higher values of R2* at the
different echo-times as previously reported [42, 60]. This can be physiologically justified
in part by the fact that the change in oxygenation in the medulla may be associated with an
almost hypoxic condition that makes it vulnerable to a further decrease in oxygen supply.
Clinicians are able to measure the creatinine levels in both blood and urine, and
thus; the filtration ability for renal transplant assessment. However, these clinical biomarkers are imprecise and usually a later stage indication of rejection, when the damage to the
kidney and the loss of renal function can be substantial. The developed Renal-CAD system integrates all available information to enhance diagnostic accuracy (93.3%), sensitivity (90.0%), specificity (95.0%), and AUC ( 0.92). This improved diagnostic ability is due
to the integration of each individual marker (i.e. Dmrks , Bmrks , and Cbmrks ) that can capture
different aspects of renal allograft dysfunction that are complementary. The Renal-CAD
system is robust to handle missing data, while still providing reasonable accuracy, as evidenced by Table 2.
In conclusion, the developed Renal-CAD system demonstrated a high classification accuracy (93.3%), sensitivity (90.0%), specificity (95.0%), and AUC (0.92) for early
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stage diagnosis of AR post-transplantation. Renal-CAD integrates individual biomarkers (i.e. clinical biomarkers with DW-MR and BOLD-MR image markers) for a better
characterization of renal allograft function and accurate identification of AR.

43

CHAPTER IV
RENAL CANCER DIAGNOSIS SURVEY

Renal cancer (RC) is considered the 10th most prevalent cancers in men and women
worldwide. Early and accurate diagnosis of renal tumors, specifically, grading and staging
of malignant tumors help identifying the aggressiveness and the spread of such tumors,
respectively. This can potentially help in administering a timely intervention with the optimal management plan. Although biopsy remains the gold standard for diagnosing renal
tumors, it is late, invasive, expensive, and has adverse affects such as bleeding and infection. In addition, it cannot assess the treatment response. Artificial intelligence (AI) when
paired with Radiomic markers resulted in developing AI-based computer-aided diagnostic
(AI-based CAD) systems, which have shown promising results for early diagnosis of renal
tumors (i.e., specifying malignancy status, subtyping, grading, and staging). Definitely,
this will help reducing diagnosis time, enhancing diagnostic performance, reducing the
need for invasive procedures, and provide the guidance for proper management to avoid
the burden of unresponsive treatment plans. This main goal of this chapter is to spot the
lights on the recent technical diagnostic studies from the last decade, with their pros and
cons, that have utilized AI and Radiomics markers extracted from computed tomography
(CT) and magnetic resonance (MR) images to produce AI-based CAD systems for precise
diagnosis of RC at an early stage.
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A.

Background on Renal Cancer

Renal cancer is 10th most common cancer among men and women. For the past
several decades, an increasing number of new patients have been diagnosed with renal
cancer. In the year 2022, approximately 79,000 new cases are expected to be diagnosed
with RC in the United States [15, 80], and 14,000 patients are expected to have died from
renal cancer in that same time period [15, 80]. Roughly two thirds of the time, renal cancer
is diagnosed before it has metastasized, in which case the 5-year survival rate is 93%. Once
it has spread to the lymph nodes or the surrounding abdominal structures (i.e., other organs
or tissues), the 5-year survival rate falls to 72%. In the worst case of metastasis to distant
parts of the body, the 5-year survival rate is a mere 15% [15, 80]. In addition, the National
Cancer Institute had an approximated cost estimate of $5.1 billion for renal cancer care
in the United States by the end of 2022 [81]. Renal cancer is a heterogeneous disease in
which the renal cells become malignant (cancerous) and form tumors called renal masses.
These renal masses, if not detected early and treated promptly, will lead to mortality.
The most common, and also the most aggressive, renal cancer is renal cell carcinoma
(RCC), accounting for 70% of all cases [82, 83]. In turn, 70% of RCC are clear cell
renal cell carcinoma (ccRCC), and of the remaining non-clear cell subtypes (nccRCC), the
most prevalent are papillary (paRCC) and chromophobe (chrRCC) renal cell carcinomas,
accounting for 15% and 5% of all RCC, respectively [84]. The World Health Organization
(WHO) taxonomy of RCC [84] has clinical significance because the various subtypes
can have very different prognoses [84–86]. Differential diagnosis of RCC must look out
for the benign tumors angiomyolipoma (AML) and oncocytoma (ONC), which are easily
confused with RCC using conventional diagnostic techniques [87–91]. AMLs with low fat
content are particularly prone to misdiagnosis [92]. Diagnostic error leads to unnecessary
surgical intervention for benign lesions, to the point where 15–20% of surgically resected
“RCC” may actually be AML [93]. Therefore, accurate characterization of such renal
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masses at an early stage is crucial to the identification of appropriate treatment plan.
Evidence of renal cancer can be found in complete blood count (CBC) to check
for the number of red blood cells; urine tests to look for blood, bacteria, or cancerous
cells in urine; and blood chemistry tests to quantify renal function by checking the levels
of certain chemicals in the blood. These signs are suggestive at best, and inadequate for
diagnosis or typing of renal cancer. Only biopsy, performed by interventional radiologists
and/or nephrologists, can provide a definite diagnosis of renal cancer, and thus remains the
gold standard [15, 80]. However, it can only be used as the last resort due to its high invasiveness, cost, and turnaround and recovery times (approximately a week). Therefore, the
investigation of noninvasive diagnostic techniques to provide an early, reliable, accurate,
cost-effective, and rapid diagnosis of renal tumors is ongoing [94–97].

B.

Related Work

Contrast-enhanced computed tomography (CECT) [98, 99], contrast-enhanced magnetic resonance imaging (CEMRI) [100], and diffusion weighted MRI (DW-MRI) [101]
are the most commonly used imaging modalities for the accurate diagnosis of renal tumors. Different contrast phases of CECTs or CEMRIs are: pre-contrast/unenhanced phase
(Phase 1), corticomedullary/arterial phase (Phase 2), nephrographic/portal-venous phase
(Phase 3), and excretory/delayed phase (Phase 4). CECT and CEMRI can specify the location, shape, and size of a given tumor and can distinguish malignant from benign lesions
with high accuracy based on their different uptake of the contrast agent [96, 102, 103]. For
DW-MRI, apparent diffusion coefficients (ADCs) are the most discriminating parameter
that quantify the Brownian motion of water molecules inside the soft tissue and thus, reveals the status of that tissue if it is normal or diseased [37, 40, 55]
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For this purpose, Radiomics are quantitative techniques that have been widely performed on CTs and MRIs to extract discriminatory markers/features for better interpretation [104, 105]. Texture, morphology, and functionality, are different aspects that could be
captured by various types of Radiomic markers, which in turn improve both the diagnostic and prediction capabilities of RC [106] at an early stage. Different types of Radiomic
markers that could be extracted from either CTs or MRIs are shown in Fig. 13. Meanwhile,
recent advances in artificial intelligence (AI), machine learning (ML), and deep learning
(DL) have accelerated the application of Radiomics in clinical practice. A typical example
of AI-based computer-aided diagnostic (AI-based CAD) system to diagnose RC is shown
in Fig. 14. It could be either hand-crafted-based pipeline or a deep learning-based one.
In both pipelines, region of interest (ROI) containing renal tumors is defined from input
CT or MR images. Then, different types of Radiomic markers are extracted, reduced, and
selected to be further processed using ML classification model. After that, diagnosis of renal tumor is then obtained and assessed using different evaluation metrics (e.g., accuracy,
sensitivity, specificity, and area under the curve (AUC)). The higher diagnostic capabilities
will help physicians to early intervene with the optimal treatment plan.
In this chapter, we will review the studies that were performed in the last decade
utilizing AI and Radiomic markers extracted from CECT, multi-parametric MRIs, CEMRI,
or DW-MRI scans to develop an AI-based CAD systems for accurate diagnosis of RC
at an early stage. In particular, identifying the malignancy status of a given renal tumor [92, 107–113], specifying the associated subtype [100, 113–116], grading and staging of malignant tumors (I-IV) [100, 117–121]. For example, Deng et al. [122] utilized
texture analysis (TA) techniques along with CECT to discriminate malignant from benign
renal tumors. Their study included 501 renal tumors of which 354 were RCCs and 147
were benign lesions. From the portal-venous phase, they manually placed a 2D ROI in
the largest CECT cross-section of the tumor volume. Then, they extracted four textural
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FIGURE 13: A typical taxonomy for the different types of Radiomics. Note that ADCs,
GLCM, GLRLM, GLSZM, GLDM, NGDTM, LBP, FFT, LTE, and DCT denote apparent
diffusion coefficients, grey-level co-occurrence matrix, grey-level run length matrix, greylevel size zone matrix, grey-level dependence matrix, neighboring gray tone difference
matrix, local binary pattern, fast Fourier transform, Law’s texture energy, and discrete
Cosine transform, respectively.

FIGURE 14: A typical pipeline for an AI-based CAD system for early diagnosis of renal
tumors using CT or MR images.
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features, namely entropy, kurtosis, mean positive pixel density, and skewness. Utilizing
logistic regression, they found that higher values of entropy were significantly associated
with a greater likelihood of malignancy (p = 0.022). As a diagnostic indicator of RCC,
the entropy feature had high specificity (85.5%), but quite low sensitivity (31.3%) [122].
Kunapuli et al. [123] conducted a study to explore the potential of CECT along with TA
to identify malignant renal tumors. Their dataset included images of 100 malignant (70
ccRCC, 20 paRCC, and 10 chrRCC) and 50 benign (20 AML and 30 ONC) tumors. After
segmenting renal tumors manually using image-rendering software, 2D and 3D TAs were
performed on tumor with the largest diameter and the entire tumor volume, respectively.
They extracted 51 2D and 3D textural features from each of four different CT phases,
yielding a total of two-hundred and four features per subject. These comprised 8 histogram features (i.e., first-order textural features), 40 second-order textural features (20
grey-level co-occurrence matrix (GLCM) and 20 grey-level difference matrix (GLDM)),
and 3 spectral features derived from the 2D Fourier transform. Recursive feature elimination [124] was used to reduce the number of features to 10 per phase, or a total of 40. Their
classification algorithm incorporating these features, using relational functional gradient
boosting, had a reported 82% accuracy and an 0.83 area under the curve. The classifier
was developed to discriminate between malignant and benign tumors only, and the authors
did not investigate the subtype classification of malignant RCC [123].
Kocak et al. [125] conducted a study to classify ccRCC renal tumors from nccRCC
ones using CECT along with TA. A total of 68 RCCs were included for internal validation
(N = 48 ccRCC and N = 20 nccRCC). For external validation purposes, they included
an additional 26 RCC from a public dataset (N = 13 and N = 13 nccRCC). Their study
utilized MaZda image-rendering software [126] to manually segment renal tumors on the
largest/middle cross-section. This was followed by an extraction of 275 textural-related
features from each subject in both the enhanced CT phase and the unenhanced phase. In
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addition, a wrapper-based nested cross-validation approach was employed to select the
reproducible features in both phases and to optimize their classification model. Artificial
neural networks (ANNs) were used, and a classification accuracy of 86.7%, a sensitivity of
80%, and a specificity of 89.6% on internal data and an accuracy of 84.6%, a sensitivity of
69.2%, and a specificity of 100% on external data were reported in differentiating ccRCC
from nccRCC. Although their study reported a good overall classification performance
between ccRCC and nccRCC, they were limited by their low sensitivity. In addition, they
reported a very poor diagnostic performance to differentiate chrRCC from paRCC and
from ccRCC. They suggested that CECT is more powerful at providing useful textural
features than the unenhanced CT. Sun et al. [127] performed a study to compare between
the diagnostic performance of machine learning approaches and four expert radiologists in
differentiating malignant from benign renal tumors, as well as ccRCC from nccRCC malignant tumors using CECT. Their study included 254 malignant tumors (ccRCC = 190,
nccRCC = 64 (chrRCC = 38, paRCC = 26)), 26 AML benign tumors, and 10 ONCs. After performing manual delineation of the tumor lesions, they used open-source software
packages to extract and analyze textural features and used another open-source software
to complete their analysis. Then, they utilized a support vector machine (SVM) classifier
with a radial basis function along with a 10-fold cross-validation approach to obtain the
final diagnosis. They reported sensitivities of 90%, 86.3%, and 73.4% using SVM compared to 73.7–96.8%, 73.7–96.8%, and 28.1–60.9% obtained by the four expert radiologists in differentiating ccRCC from nccRCC, ccRCC from AML and ONC, and nccRCC
from AML and ONC, respectively. Hence, they concluded that ML approaches along with
textural features have potential power, as well as low-variance performance in diagnosing
renal tumors.
Lee et al. [128] used TA and CECT in their study to differentiate between ccRCC
malignant and AML benign renal tumors. Their study included 80 renal tumors (ccRCC =
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41 and AML = 39). They combined several hand-crafted textural features extracted from
a 2D manually annotated central image of the entire mass with automated deep features
extracted by different ImageNet pretrained convolutional neural network (CNN) classification models, namely AlexNet [129], VGGNet [130], GoogleNet [131], and ResNet [132].
Then, they used the combined features to train and test a random forest (RF) classifier.
Using a leave-one-out cross-validation approach, their combined model achieved a diagnostic accuracy of 76.6% ± 1.4%, outperforming the individual diagnostic results using
either the hand-crafted features alone or the deep features alone. The reported results were
not accurate enough to consider the developed an independent diagnostic tool. Oberai et
al. [133] investigated the potential power of CNN along with multi-phasic CECT images to
differentiate benign from malignant renal masses. Their study included 143 patients (malignant = 97 and benign = 46). After performing manual segmentation of the whole tumor
volume, they selected the largest axial segmented tumor image from each CECT phase
to fed to the CNN for training and validation. Using an 8-fold cross-validation approach,
they reported an accuracy of 78%, a sensitivity of 70%, and a specificity of 81%. However, their dataset had class imbalance, which might contribute to the reduced diagnostic
performance. Although their study included different types of malignant tumors, they did
not investigate the subtyping of malignant class. Zhou et al. [134] conducted a study to
distinguish malignant from benign renal tumors using CECT along with an ImageNetpretrained InceptionV3 model. This model was then cross-trained using transfer learning
on their own dataset of 192 renal tumors (malignant: ccRCC = 117 and nccRCC = 17,
benign: renal cyst = 50 and AML = 8). Several image-level models were considered,
using whole CT slices, ROIs, and rectangular subregions of the CT-CT data. Then, during the transfer learning, different number of layers were frozen, resulting in two-patient
level models based on the optimal image-level models. Using a five-fold cross-validation
approach, they reported a 69% accuracy using the slice dataset, a 97% accuracy using
the ROI dataset, and a 93% accuracy using the RBR dataset. In spite of achieving a high
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accuracy in differentiating malignant from benign renal tumors, 50 out of 58 benign cases
were renal cysts, which are much easier to distinguish from RCC compared to AML. In
addition, they did not investigate discriminating ccRCC from nccRCC renal tumors.
In differentiating benign from malignant renal tumors, [92, 107] found that firstand second-order texture features extracted from unenhanced CT achieved an accuracy
range of (82% - 91%) and an AUC range of (0.73 - 0.90) using SVM classifiers. While
[108, 135–137] reported that first- and second-order texture features extracted from multiphasic CECT achieved an accuracy range of (72% - 94%) and an AUC range of (0.75 0.97) using SVM classifiers. Yan et al. [138], Ma et al. [139], and Tang et al. [140] agreed
with their findings regarding the texture features from multi-phasic CECT. However, Yan
et al. [138] rather suggested ANNs and achieved an accuracy of 97% on a slightly small
unbalanced dataset (N = 50), while Ma et al. [139] and Tang et al. [140] reported an AUC
range of (0.67 - 0.93) on logistic regression (LR) classifiers instead. An extended study by
Ma et al. [139] suggested the superiority of phase 3 of CECT by an AUC range of (0.74 0.89). In addition to first and second order texture features, Nassiri et al. [141] integrated
higher order texture features and shape features extracted from phase 3 of CECT and
achieved an accuracy range of (74% - 79%) and an AUC range of (0.77 - 0.84) using
RF and Adaboost classifiers. While Yap et al. [142] integrated the same features but
from multi-phasic CECT and achieved an AUC range of (0.65 - 0.75). Uhlig et al. [116]
achieved an accuracy of 84% and AUC of 0.83 using a RF classifier without the need
for higher-order features. Using DL on multi-phasic CECT, Coy et al. [143] achieved the
best diagnostic performance (74% accuracy) on phase 4 of CECT. Kim et al. [144] found
that entropy as a first order texture feature extracted from unenhanced CT is statistically
significant and can differentiate RCC from benign cysts using LR with an AUC of 0.92.
Tanaka et al. [145] used DL approach based on Inception-V3 CNN with data augmentation
and achieved an accuracy range of (41% - 88%) and an AUC range of (0.49 - 0.85) and
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promoted phase 2 of CECT than over other contrast phases. Li et al. [146] differentiated
malignant chrRCC from benign ONC using first and second order features extracted from
multi-phasic CECT and achieved an accuracy of 0.95 and AUC of 0.85 using an SVM
classifier. They suggested that phases 2 and 3 are superior to other contrast phases for the
specified task. Then, they extended their studies [147, 148] for the same differentiation
problem on bigger datasets and suggested that integrating some clinical factors enhanced
the final diagnostic performance. Zabihollahy et al. [149] utilized 2D and 3D CNNs on
ROIs around the tumor and reported an accuracy range of (77% - 84%).
For the subtyping of RCC tumors, studies [114, 150] suggested that first-order texture features such as mean, standard deviation (STD), kurtosis, skewness, entropy, and
median extracted from phase 3 of CECT are of high significance for RCC subtyping.
Deng et al. [114] reported a very low accuracy of 47% and an AUC of (0.80 - 0.84) using LR and Yu et al. [150] reported an AUC of range (0.86 - 0.92) using SVM. Zhang et
al. [115] agreed with them on the significant features, however they extracted them from
phase 2 rather than phase 3 of CECT and achieved an accuracy range of (78%-0.87%) and
an AUC range of (0.94 - 0.96) using an SVM classification model. Verghase et al. [151]
suggested that many of the first-, second-, and higher-order texture features extracted from
multi-phasic CECT are of high importance and achieved an AUC range of (0.80 - 0.98)
using stepwise LR as a statistical analysis method. On two consequent studies by Uhlig
et al. [116, 152], they promoted first- and second-order texture features as well as shape
features extracted from phase 3 of CECT. They demonstrated an accuracy range of (54%
- 92%) and an AUC range of (0.45 - 0.85) using RF and XGBoost classifiers. Chen et
al. [153] suggested that second-order texture features extracted from phase 3 of CECT
achieved an accuracy range of (82% - 88%) and an AUC range of (0.86 - 0.90) using LR.
For grading and staging of RCC tumors, Feng et al. [117] found that entropy, STD,
and kurtosis extracted from multi-phasic CT are statistically significant first-order texture
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features and reported an accuracy range of (70% - 79%) and an AUC range of (0.74 0.83). Shu et al. [118] suggested that first- and second- order texture features and shape
features extracted from phases 2 and 3 of CECT are useful Radiomic markers and reported
an accuracy range of (72% - 78%) and an AUC range of (0.77 - 0.82) using LR classifier.
They extended their study on a slightly larger dataset and excluded the shape features.
In addition, they used SVM and RF classifiers instead of LR and reported an improved
accuracy range of (92% - 94%) and AUC range of (0.96 - 0.98). Two studies [154, 155]
extracted second order texture features from phases 2 and 3 of CECT. Ding et al. [154]
reported an AUC ≥ 0.67 using LR classifier, while Yin et al. [155] reported an AUC
of 0.86 using a SVM classifier. Bektas et al. [156] suggested that second- and higherorder texture features extracted from phase 3 of CECT are very useful evidenced by an
accuracy of 85% and an AUC of 0.86 using a SVM classifier. Lin et al. [157] found that
first- and second-order texture features extracted from multi-phasic CECT can grade renal
tumors with an accuracy of 74% and an AUC of 0.87 using gradient boosting decision
tree classifier. Momenian et al. [158] suggested that first-order texture features extracted
from phase 2 of CECT can potentially grade ccRCC tumors using a RF classifier with an
accuracy of 97%. Lai et al. [159] found that first-order texture features and shape features
extracted from unenhanced CT can grade ccRCC tumors using a Bagging classifier with an
AUC of 0.75. Luo et al. [160] reported that first-order texture features and shape features
extracted from phases 1 and 4 of CECT demonstrated an accuracy of 81% and an AUC of
87% using a RF classifier. Yi et al. [161] suggested that using first-, second-, and higherorder texture features extracted from unenhanced CT can grade ccRCC tumors using SVM
(accuracy = 90% and AUC = 0.91). He et al. [162] agreed with Yi et al. [161] on the type
of features but contradict with him on the CECT phases where they should be extracted.
He rather suggested phases 2 and 3 of CECT and achieved an accuracy range of (91% 94%) using ANNs. Xu et al. [163] used an ensamble of different types of DL networks
on 2D ROIs at phase 2 of CECT. They reported an accuracy of 82% and and AUC of
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0.88. Demirjian et al. [119] conducted a study for both grading and staging of ccRCC
tumors. For the grading, they extracted multiple second-order texture features as well as
the mean intensity as a first order texture feature from multi-phasic CECT. While for the
staging, they depended only on the second-order texture features. Using RF classifiers,
they achieved an AUC of 0.73 and 0.77 for grading and staging, respectively.
Table 7 provides summary of the aforementioned AI-based CAD systems that have
been developed, in the last decade, by utilizing multi-phasic CECT images. The Table
encompasses the following details: study, main goal, Radiomics, methods, results, and
findings.
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TABLE 7: Summary of studies utilized CT for renal cancer diagnosis in the last decade.

Study

Main Goal

Radiomics

Method

Results

Findings

Yang

Differentiation

• Shape: 12

• 2D ROI

• Acc: 0.82

Radiomics

et al. [107]

of small (≤ 4

• 1 st Order Statistics: 17

• SVM

• Sen: 0.83

• 2nd Order Statistics: 74

• 5-fold CV
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cm)
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and RCC renal
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(N

phasic

tracted

CECT

images
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unenhanced
CT

=

163) using multi-

ex-

phase

are

sufficient
• AUC: 0.90

– GLCM: 23

to

accurately differentiate AMLwvf

– GLRLM: 16

from RCC using

– GLSZM: 16

SVM
– NGTDM: 5
– GLDM: 14
You

Differentiation

et al. [108]

of small (≤ 4
cm)
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and RCC renal
tumors (N = 67)
using four phases
of CECT images

• 1 st Order Statistics: 3

• 2D ROI

• Acc: 0.85

– Phase 1: 2

• SFS

• Sen: 0.82

– Phase 4: 1

• SVM

• Spe: 0.76

• k-fold CV

• AUC: 0.85

Radiomics

of

small

renal

masses extracted
from

multi-

phasic CECT can

• 2nd Order Statistics: 2

accurately differentiate AMLwvf

– Phase 2:

from

1 (GLCM)

ccRCC

using SVM
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1 (GLRLM)
• RGB encoding of the

Coy

Differentiation

et al. [143]

of ccRCC from

entire tumor volume in

ONC renal tu-

Phase 4

mors (N = 179)

• 3D ROI

• Acc: 0.74

• TL of GTf

• Sen: 0.86

• k-fold CV

• Spe: 0.44

using four phases

Radiomics

ex-
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from

3D VOI of the
entire

tumor

demonstrated the
• AUC: —

of CECT images

best

diagnostic

performance

in

Phase 4 of CECT
using TL of GTf
Continued on next page
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TABLE 7 – Continued from previous page
Study

Main Goal

Deng

Subtyping

et al. [114]

RCC

(Study 1)

Radiomics

Method

Results

Findings

• 1 st Order Statistics: 4

• 2D ROI

• Acc: 0.47

Entropy

– mean

• Holm-P

• Sen: 0.31

relation with its
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grade (N = 298)

– kurtosis
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(Statistical
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CECT images
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ccRCC

< 0.05).

(p
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entropy is correlated with high
grade RCC.
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3 of CECT im-
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et al. [122]
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Entropy

had
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RCC than benign
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and could poten-
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RCC

Multi-channel

(RGB) 2D ROI images

and benign renal
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phase of CECT
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Deep

learning

has the potential
to
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• Spe: 0.97
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images
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Differentiation

et al. [144]

between
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RCC

and benign renal
=

cysts
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unenhanced
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(N
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• Acc: 0.84
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CT
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images

The
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using Radiomics
provided AUC of
0.92
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TABLE 7 – Continued from previous page
Study

Main Goal

Radiomics

Method

Results

Findings

Nie

Differentiation of

• Shape: 2

• 3D ROI

• Acc: 0.84

Radiomics

et al. [164]
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– Phase 2: 1

• LASSO
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– Phase 3: 1
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ccRCC
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=
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CECT
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images
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0.017

– Phase 2: 1
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diagnosis
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=
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CECT images
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different

Radiomics

• Spe: —
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– GLDM: 7
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are
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differentiating
benign
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TABLE 7 – Continued from previous page
Study

Main Goal

Radiomics

Method

Results

Findings

Tang

Differentiation

• 1 st Order Statistics: 24

• 2D ROI

• Acc: range

Integrating differ-

et al. [140]

between

• 2nd Order Statistics: 52

• 100% Data Aug-

(0.8 - 0.92)
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and

RCC
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renal tumors (N
=
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mentation
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of
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CECT images
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and
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renal
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– LTE: 120
Cui
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et al. [135]
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(0.84 - 0.93)
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CECT images
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=

•

Order Statistics: 3

• 2D ROI

• Acc: 0.72

• 2nd Order Statistics: 1

• ReliefF

• Sen: 0.72

• kNN, SVM

• Spe: 0.73

• 5-fold CV

• AUC: 0.75

1 st

– GLCM: 1

Proper selection
and

of optimal Radiomics

50) using multiphasic

integration

and

machine learning

CECT

images

classification
methods
potentially

could
help

distinguishing
AMLwvf

from

ccRCC
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Lee

Differentiation of

• Shape: 7

• 2D ROI

• Acc: range

The

et al. [128]

AMLwvf

from

(Study 2)

ccRCC

renal

• 1 st Order Statistics: 18

• RF

tumors

renal

• 2nd Order Statistics: 53

• k-fold CV

tumors (N = 80)
– GLCM: 14

using four phases
of CECT images

• Sen: range
(0.73 - 0.79)
• Spe: range

– GLDM: 22

(0.75 - 0.77)

model

that

integrates
hand-crafted
Radiomics

with

deep Radiomics
provided an enhanced diagnos-

– LBP: 10
• 1000-4000

(0.75 - 0.77)

combined

• AUC: range
(0.79 - 0.82)

dimensional

tic

performance

than

individual

deep features extracted

models and thus;

from

has the potential

ImageNet

pre-

trained models (AlexNet,

to

VGGNet, GoogleNet, and

AMLwvf

ResNet) with small renal

ccRCC.

distinguish
from

mass image patches.
Feng

Differentiation

et al. [137]

of small (≤ 4

(Study 1)

cm)

AMLwvf

from RCC renal
tumors

(N

• 1 st Order Statistics: 8

• 2D ROI

• Acc: 0.94

• 2nd Order Statistics: 3

• RFE

• Sen: 0.88

• SVM

• Spe: 1.00

• SMOTE

• AUC: 0.96

– GLCM: 3

SMOTE can help
selecting
mal

CECT

of

SVM, RFE, and

=

58) using multiphasic

Combination

opti-

Radiomics

that could accurately distinguish

• 5-fold CV

images

AMLwvf

from

RCC
Feng

Grading

et al. [117]

ccRCC

(Study 2)

tumors

of

• 1 st Order Statistics: 5

• 2D ROI

renal
(N

=

131) using threephases of CECT

• t-test (Statistical

– mean

analysis only)

– entropy

• Acc: range
(0.70 - 0.79)
• Sen: range
(0.76 - 0.95)

– STD

images

• Spe: range

– skewness

(0.54 - 0.77)
– kurtosis

Entropy,
and

kurtosis

were statistically
significant

(p

< 0.05) and are
useful Radiomic
markers to grade
ccRCC

• AUC: range

STD,

renal

tumors.

(0.74 - 0.83)
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Yan

Differentiation

• 1 st Order Statistics: 11

• 2D ROI

• Acc: range

Optimal

et al. [138]

of

• 2nd Order Statistics: 220

• NDA

AMLwvf

from ccRCC and
paRCC

renal

tumors

• kNN, ANN

– GLCM: 220

=

(N

• 5-fold CV

50) using multiphasic

(0.97 - 1.00)

diomics extracted
from

• Sen: —

multi-

phasic CT images
have the power

• Spe: —

to
• AUC: —

CECT

Ra-

distinguish

AMLwvf

images

from

ccRCC

and

paRCC
Hodgdon

Differentiation

et al. [92]

of

AMLwvf

from
nal
=

RCC

re-

tumors

(N

100)

unenhanced

• 1 st Order Statistics: 2

• 2D ROI

• 2nd Order Statistics: 7

• Holm-P

– GLCM: 5

• SVM

– GLRLM: 2

• 10-fold CV

using
CT

• Acc: range
(0.83 - 0.91)

ex-

tracted

from

unenhanced

• Sen: —
• Spe: —

CT

images

can

distinguish

AMLwvf
• AUC: range

images

Radiomics

from

RCC

(0.73 - 0.90)
Tanaka

Differentiation of

et al. [145]

benign from malignant renal tumors (N = 168)
using four phases
of CECT images

• 2D ROI images around the
lesion (299 × 299)

• 2D ROI
• Augmentation

• Data augmentation was
performed using rotation
(90°, 180°, and 270°),
mirroring, and the ad-

• Inception-V3

• Acc: range
(0.41 - 0.88)
• Sen: range
(0.29 - 0.96)

CNN
• 20% testing

dition of gaussian noise

• Spe: range
(0.33 - 1.00)

Deep

learning

has the potential
to

distinguish

malignant

from

benign

renal

tumors

espe-

cially in Phase 2
of CECT (corti-

(0.05, 0.10, and 0.15)

• AUC: range

comedullary/Arterial)

(0.49 - 0.85)
kunapuli

Differentiation of

et al. [123]

benign from malignant renal tumors (N = 150)

• 1 st Order Statistics: 2

• 2D/3D ROI

• Acc: 0.82

• 2nd Order Statistics: 8

• RFE

• Sen: —

– GLCM: 7

• RFGB

• Spe: —

– GLDM: 1

• 10-fold CV

• AUC: 0.83

RFGB

machine

learning classifier
and

Radiomic

markers can be
potentially

using four phases
of CECT images

to

used

distinguish

malignant

from

benign

renal

tumors
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Ma

Differentiation of

• Total: 6

• 3D ROI

• Acc: —

Combined model

et al. [139]

AMLwvf

from

(Study 1)

ccRCC

renal

• 1 st Order Statistics: —

• LASSO

• Sen: —

• 2nd Order Statistics: —

• LR

• Spe: —

• 30% testing

• AUC: range

tumors

=

(N

integrating

84) using multiphasic

CECT

diomics

from

different

phases

of
– GLCM: —

(0.83 - 0.93)

images

ra-

CECT

en-

hanced

the

diagnostic performance

between

AMLwvf

and

ccRCC

when

compared to individual models
as well as the
conventional CT
Ma

Differentiation of

et al. [165]

AMLwvf

from

(Study 2)

ccRCC

renal

tumors (N = 230)

• Total: 396

• 3D ROI

• Shape: —

• LASSO

• 1 st Order Statistics: —

• 30% validation

using four phases
of CECT images

• 2nd Order Statistics: —

• Acc: range
(0.69 - 0.80)
• Sen: range
(0.66 - 0.79)
• Spe: range
(0.76 - 0.85)

– GLCM: —

The

perirenal

model

using

Radiomics from
Phase 3 of CECT
has

superiority

than other phases
to

distinguish

AMLwvf

Li

Differentiation

et al. [146]

between chrRCC

(Study 1)

and ONC renal
tumors (N = 61)
using four phases
of CECT images

– GLRLM: —

• AUC: range

– GLSZM: —

(0.74 - 0.89)

• 1 st Order Statistics: 3

• 3D ROI

• Acc: 0.95

– Phase 2 & 3: 2

• LASSO

• Sen: 0.99

– Phase 4: 1

• SVM

• Spe: 0.80

• 5-fold CV

• AUC: 0.85

from

ccRCC.

Radiomics
tracted

exfrom

multi-phasic
CECT

can

accurately differ-

• 2nd Order Statistics: 5

entiate

chrRCC

from ONC using

– Phase 2 & 3:

SVM

3 (GLCM)
– Phase 2 & 3:
2 (wavelet)
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Li

Differentiation

• 1 st Order Statistics: 5

• 3D ROI

• Acc: 0.81

Radiomics

et al. [147]

of

– Phase 2: 2

• LR, LASSO

• Sen: 0.86

– Phase 3: 3

• Nomogram

• Spe: 0.83

• Rad-score

• AUC: 0.84

(Study 2)

ONC

from

ccRCC

renal

tumors

=

(N

122) using multiphasic

CECT

images

tracted

exfrom

multi-phasic CT
can

differenti-

ate ONC from

• 2nd Order Statistics: 6
– Phase 2:

ccRCC. By integrating

• 30% validation

clinical

2 (GLCM),

factors, enhanced

1 (GLSZM)

diagnosis is obtained

– Phase 3:

(Acc

=

0.87, Sen = 0.86,

1 (GLCM)

Spe = 0.87, and

– Phase 4:

AUC = 0.90)

2 (GLCM)
• Acc: 0.91

– Phase 2: 1

• LR, LASSO

• Sen: 0.84

mors with present

– Phase 3: 2

• Nomogram

• Spe: 0.95

central scar (N

– Phase 4: 2

• Radscore ≥ -0.55

• AUC: 0.96

Differentiation

et al. [148]

of

(Study 3)

• 1 st Order Statistics: 5

• 3D ROI

Li

ONC

from

chrRCC renal tu-

=

141)

CECT images

tracted

• 2nd Order Statistics: 7

• 40% validation

multi-phasic
CT can differONC

from

chrRCC.

By

integrating

clinical

– Phase 2:

a

2 (GLCM),

exfrom

entiate

using

multi-phasic

Radiomics

factors,

Nomo-score

≥ 0.19 provides

1 (GLSZM)

better
– Phase 3:

diagnosis

(Acc = 0.95, Sen

2 (GLCM)

= 0.90, Spe =
0.97, and AUC =

– Phase 4:

0.99)

2 (GLCM)
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Nassiri

Differentiation

• Shape: —

• 3D ROI

• Acc: range

Radiomics from

et al. [141]

of benign from

• 1 st Order Statistics: —

• RF, Adaboost

malignant
tumors

renal
(N

=

• 10-fold CV

• 2nd Order Statistics: —

684) using multiphasic

CECT

images

– GLCM: —

(0.74 - 0.79)
• Sen: range
(0.73 - 0.80)
• Spe: 0.75

Phase 3 of CECT
can

potentially

distinguish
benign

from

malignant

renal

tumors. Integrat-

– GLDM: —
• AUC: range
– GLRLM: —

(0.77 - 0.84)

– NGDTM: —

ing some clinical
factors enhanced
the

diagnostic

performance.

– GLSZM: —
• Higher Order Stats: —
– DCT: —
– FFT: —
– LTE: —
Uhlig

Differentiation of

et al. [116]

benign from ma-

(Study 1)

lignant renal tumors (N = 94)

• Total: 120

• 3D ROI

• Acc: 0.84

• Shape: —

• RFE

• Sen: 0.88

• 1 st Order Statistics: —

• RF

• Spe: 0.67

• 2nd Order Statistics: —

• 10-fold CV

• AUC: 0.83

Radiomic markers Phase 3 of
CECT and machine

using Phase 3 of
CECT images

can

– GLCM: —
– GLDM: —

learning
potentially

distinguish
benign

from

malignant

renal

tumors.

– GLRLM: —
– NGDTM: —
– GLSZM: —
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Uhlig

Renal

• Total: 127

• 3D ROI

• Acc: range

Radiomic mark-

et al. [152]

subtyping

(Study 2)

=

• Shape: —

• SMOTE, RFE

201)

tumors
(N
using

Phase 3 of CECT

• 1 st Order Statistics: —

• XGBoost, RF

• 2nd Order Statistics: —

• 10-fold CV

images

(0.54 - 0.92)
• Sen: range
(0.05 - 0.80)
• Spe: range

– GLCM: —

(0.41 - 0.97)

– GLDM: —

• AUC: range

ers Phase 3 of
CECT and machine
can

learning
potentially

help distinguishing renal tumors
subtypes.

(0.45 - 0.85)

– GLRLM: —

Dif-

ferentiation

of

ONCs is still a
challenging task.

– NGDTM: —
– GLSZM: —
Uhm

Subtyping of re-

• 3D Channel image of size

et al. [166]

nal tumors (N =

224 × 224 cropped from

308) using multi-

2D ROI image with the

phasic CECT im-

largest segmented tumor

ages

at Phases 2, 3, &4

• 2D ROI

• Acc: 0.72

• 16% validation

• Sen: range

• (N = 184) external test

Deep

(0.60 - 0.89)
• Spe: range
(0.87 - 0.97)

• ResNet-101 was initial-

learning

outperformed
radiological

di-

agnosis of renal
tumors

using

multi-phasic
CECT.

ized with weights ob-

• AUC: 0.89

tained from a pre-trained
ImageNet.
Zabihollahy

Differentiation of

et al. [149]

RCC from benign

• 2D ROI images around the
tumor (512 × 512)

• 2D ROI
• MJV

renal tumors (N =
315) using CECT

• 2D & 3D CNN

images
• 50% testing

• Acc: range
(0.77 - 0.84)
• Sen: range
(0.84 - 0.92)
• Spe: range
(0.26 - 0.52)

Semi-automated
MJV

demonstrated the
best

diagnostic

performance

in

differentiating
RCC from benign
renal

• AUC: —

2D-CNN

tumors

using CECT.
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Yap

Differentiation

• Total: top 10% (79)

• 3D ROI

• Acc: —

The

et al. [142]

between

• Shape: —

• RF, AdaBoost

• Sen: —

• 1 st Order Statistics: —

• 10-fold CV

• Spe: —

malig-

nant and benign
renal tumors (N
=

735)

model integrating
shape and texture

using

CECT images

Radiomic

markers extracted
• 2nd Order Statistics: —

multi-phasic

combined

• AUC: range
(0.65 - 0.75)

– GLCM: —

from all phases of
CECT enhanced
the final diagnos-

– GLDM: —

tic performance.

• Higher Order Stats: —
– FFT: —
Yu

Differentiating

et al. [150]

benign

from

malignant

renal

tumors as well

• 1 st Order Statistics: 14

• 2D ROI

• Acc: —

• 2nd Order Statistics: 20

• SVM

• Sen: —

• 5-fold CV

• Spe: —

– GLCM: 5

Machine learning
and 1 st Order Radiomic

such as kurtosis,

as subtyping (N
=

skewness,
– GLRLM: 11

119)

images

• AUC: range

using

Phase 3 of CECT

markers

(0.86 - 0.92)

– GLGM: 4

and

median provides
high

diagnostic

performance

• Higher Order Stats: 9

different

of
renal

tumors’ types.

– LTE: 9
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Shu

Differentiating

• Shape: 5

• 3D ROI

• Acc: range

Radiomic mark-

et al. [118]

low grade from
high

grade

ccRCC (N = 260)
using Phase 2 &3
of CECT images

• ICC, LASSO

– Phase 2: 1
– Phase 3: 4

• LR

• 1 st Order Statistics: 9

• 5-fold CV

(0.72 - 0.78)
• Sen: range
(0.60 - 0.69)
• Spe: range

– Phase 2: 3

(0.83 - 0.84)

– Phase 3: 6

• AUC: range

ers

extracted

from

combined

Phases 2 & 3 of
CECT could be
potentially
for

grading

used
of

ccRCC
(0.77 - 0.82)

• 2nd Order Statistics: 21
– Phase 2:
2 (GLCM),
3 (GLSZM),
2 (GLRLM)
– Phase 3:
3 (GLCM),
8 (GLSZM),
3 (GLRLM)
Shu

Differentiating

et al. [167]

low grade from
high

grade

ccRCC (N = 271)
using Phase 2 &3
of CECT images

• 1 st Order Statistics: 4

• 3D ROI
• ICC, LASSO

– Phase 2: 1
– Phase 3: 3

• SVM, RF, MLP

• 2nd Order Statistics: 8

• 40% validation

– Phase 2:

• Acc: range
(0.92 - 0.94)
• Sen: range
(0.92 - 0.97)
• Spe: range
(0.86 - 0.95)

Radiomic markers

extracted

from

combined

Phases 2 & 3
of CECT could
be

sufficiently

used for grading
of ccRCC using

1 (GLCM),

• AUC: range

3 (GLRLM)

machine learning.

(0.96 - 0.98)
– Phase 3:
2 (GLCM),
1 (GLRLM),
1 (GLSZM)
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Ding

Differentiating

• 2nd Order Statistics: 4

• 2D ROI

• Acc: —

Radiomic mark-

et al. [154]

low grade from

• LASSO

• Sen: —

• LR

• Spe: —

• (N = 92) external

• AUC: ≥ 0.67

high

grade

ccRCC (N = 114)
using Phase 2 &3
of CECT images

– Phase 2:
1 (GLRLM)

ers

from Phases 2 &
3 of CECT could

– Phase 3:

be

3 (GLCM)

test
• 2nd Order Statistics: 8

Bektas

Differentiating

et al. [156]

low grade from
high

grade

ccRCC (N = 54)
using Phase 3 of
CECT images

– Phase 3:

3 (GLRLM)

• Acc: 0.85

• wrapper, Nested

• Sen: 0.91

• SVM

• Higher Order Stats: 5

potentially

used for grading
of ccRCC

• 2D ROI

10-fold CV

5 (GLCM),

extracted

Machine learning
(e.g.,
and

SVM),
Radiomics

extracted

• Spe: 0.80

from

Phases 3 provide
• AUC: 0.86

a

promising

diagnostic
– Phase 3:

tool

to grade ccRCC

4 (wavelet),

renal tumors

1 (gradient)
kocak

Subtyping

of

et al. [125]

RCC (N = 68)
using Phase 1 &2
of CECT images

• 1 st Order Statistics: 9

• 2D ROI
• wrapper, Nested

– Phase 1: 5

10-fold CV

– Phase 2: 4

• SMOTE

• 2nd Order Statistics: 16

• SVM, ANN

– Phase 1:
3 (GLCM)

• (N = 26) external
test

– Phase 2:

• Acc: range
(0.69 - 0.85)
• Sen: range
(0.69 - 0.71)
• Spe: 1.00

Radiomics

ex-

tracted

and

combined
Phases

from
1

&

2 (Phase 2 is
superior) can distinguish nccRCC

• AUC: —

from

ccRCC

using

machine

learning. Distin-

13 (GLCM)

guishing ccRCC,
• Higher Order Stats: 5

paRCC, chrRCC
is challenging

– Phase 1:
4 (wavelet),
1 (autoagressive)
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Sun

Differentiating

• 1 st Order Statistics: 1

• 2D ROI

• Acc: 0.87

Radiomics

ex-

et al. [168]

low grade from

• ICC, LASSO

• Sen: 0.83

tracted

and

• SVM

• Spe: 0.89

• 20% validation

• AUC: 0.91

high
ccRCC

– Phase 2 & 3:

grade

RMS

=

(N

227) using three

combined

Phases 2 & 3
of

• 2nd Order Statistics: 6

phases of CECT
– Phase 2 & 3:

images

from

CECT

sufficiently grade
ccRCC

1 (GLCM),

can

renal

tumors on SVM

3 (GLSZM),
2 (GLRLM)
•

Lin

Differentiating

et al. [157]

low grade from
high
ccRCC

grade
=

(N

1 st

• 2D ROI

Order Statistics: 6

• 2nd Order Statistics: 16

• Acc: 0.74

• CatBoost

• Sen: 0.14

– GLCM: 4

• GBDT

• Spe: 0.88

– GLDM: 4

• 5-fold CV

• AUC: 0.87

et al. [115]

ccRCC
nccRCC

classify nccRCC
subtypes (N =

ccRCC

renal

– NGDTM: 1

tumors

using

machine learning

• 1 st Order Statistics: 4

• 2D ROI

– mean

• CatBoost

– STD

• SVM

– entropy

• 10-fold CV

127) using multiphasic

CECT

potentially grade

– GLRLM: 4

from
and

from

Phases 1, 2 &

– GLSZM: 3
Differentiating

and

3 of CECT can

phases of CECT

Zhang

ex-

tracted
combined

232) using three

images

Radiomics

– kurtosis

• Acc: range
(0.78 - 0.87)
• Sen: range
(0.87 - 0.89)

Radiomics
tracted

are

sufficient

for

subtyping
RCC

tumors
• AUC: range

images

from

Phase 2 of CECT

of

• Spe: 0.92

ex-

renal
using

SVM

(0.94 - 0.96)
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ccRCC
tumors

of
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• 1 st Order Statistics: 6

• 2D ROI

• Acc: range

Radiomics

ex-

tracted

and

renal
(N

=

227) using multiphasic

Radiomics

CECT

• LASSO

– Phase 2: 4
– Phase 3: 2

• ANN

• 2nd Order Statistics: 14

• 15% validation

– Phase 2:

• 15% testing

(0.91 - 0.94)
• Sen: —
• Spe: —

combined

Phases 2 & 3 of
CECT are sufficient for grading

• AUC: —

of

RCC

tumors

7 (GLCM),
• 10-fold CV

3 (GLRLM)

from

renal
using

ANN

– Phase 3:
3 (GLCM),
1 (GLRLM)
• Higher Order Stats: 9
– Phase 2:
1 (gradient),
4 (wavelet)
– Phase 3:
1 (gradient),
3 (wavelet)
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Momenian

Grading

• 1 st Order Statistics: 18

• 2D ROI

• Acc: 0.97

1 st

et al. [158]

ccRCC

– Phase 1: 6

• RF

• Sen: —

103) using three

– Phase 2: 6

• 10-fold CV

• Spe: —

phases of CECT

– Phase 3: 6

tumors

of
renal
(N

=

Order

Ra-

diomics extracted
from Phase 2 of
CECT had shown
the best grading

• AUC: —

images

performance

• 2nd Order Statistics: 93

ccRCC

of
renal

tumors using RF

– Phase 1:

outperforming

20 (GLCM),

2nd

the

11 (GLRLM)

Order

Radiomics alone
– Phase 2:

and

20 (GLCM),

combined

Radiomics.

11 (GLRLM)
– Phase 3:
20 (GLCM),
11 (GLRLM)
Yin

Grading

et al. [155]

ccRCC

of

•

2nd

Order Statistics: 10

renal
– Phase 2:

tumors (N = 78)

7 (GLCM),

using Phase 2 of

3 (GLRLM)

CECT images

• 2D ROI

• Acc: 0.88

• ICC, SMOTE

• Sen: 0.80

• SVM

• Spe: 0.90

• 32% testing

• AUC: 0.86

2nd

Order

Ra-

diomics extracted
from
of

Phase

CECT

vided

the

2
probest

grading accuracy
of ccRCC renal

• 10-fold CV

tumors on SVM
•

Chen

Differentiating

et al. [153]

of ccRCC from
nccRCC
tumors

renal
(N

=

197) using multiphasic
images

CECT

2nd

• 3D ROI

Order Statistics: 9

• LASSO

– Phase 1:
3 (GLCM),

• SMOTE

1 (GLRLM)

• LR

– Phase 2:
1 (GLCM)

• Acc: range
(0.82 - 0.88)
• Sen: range
(0.81 - 0.89)
• Spe: range
(0.81 - 0.88)

2nd

Order

diomics
combined

Rawhen
with

non-texture
markers extracted
from Phase 3 of
CECT, the best
differentiation

– Phase 3:

• AUC: range

1 (GLCM),
(0.86 - 0.90)
1 (GLSZM)

of ccRCC from
nccRCC

renal

tumors( AUC =
– Phase 4:

0.9) was obtained

2 (GLCM)
Continued on next page
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TABLE 7 – Continued from previous page
Study

Main Goal

Lai

Grading

et al. [159]

ccRCC
tumors

of

Method

Results

Findings

• Shape: 5

• 2D ROI

• Acc: —

Shape

• CMIM

• Sen: —

• SMOTE

• Spe: —

• Bagging

• AUC: 0.75

renal
(N

=

137) using multiphasic

Radiomics

– Phase 1: 5
• 1 st Order Statistics: 5

1 st

Order Radiomics
extracted

from

Phase 1 of CECT

CECT

demonstrated the
– Phase 1: 5

images

and

mean,

best ccRCC grading performance

• 5-fold CV

median,

(AUC

RMS,

using

10th

classifier

Pctl,

=

0.75)

Bagging

90th Pctl
Yi

Grading

et al. [161]

ccRCC

of

• 1 st Order Statistics: 6

renal

tumors (N = 264)
using Phases 1

Phase
– 1: 6
• 2nd Order Statistics: 9

• 2D ROI

• Acc: 0.90

• ICC, LASSO

• Sen: 0.94

• SVM

• Spe: 0.89

• 25% validation

• AUC: 0.91

Radiomic markers

from Phase 1 of
CECT can suc-

& 3 of CECT
Phase
– 1: 9 (GLRLM)

images

extracted

cessfully

grade

ccRCC

renal

tumors (AUC =

• Higher Order Stats: 4

0.91) using SVM
Phase
– 1: 4 (wavelet)
of

• 2D ROI images (224 ×

renal

224 × 3) as input to VGG-

tumors (N = 706)

16 pre-trained on Ima-

using Phase 2 of

geNet for segmentation.

Xu

Grading

et al. [163]

ccRCC

CECT images

• Self-supervised
training

using

• Acc: 0.82

• VGG-16

• Sen: 0.86

• Ensamble

• Spe: 0.75

• 16% validation

• AUC: 0.88

Deep learning applied on Phase 2
of CECT images
can

potentially

grade ccRCC repreReg-

NetY400MF,

Reg-

NetY800MF,

SE-

ResNet50,

• 2D ROI

ResNet101,

and Ensamble.

nal tumors (AUC
= 0.88) using Ensamble/combined
model
forming

outperall

individual models.
Continued on next page
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Study

Main Goal

Luo

Grading

et al. [160]

ccRCC

of

Radiomics

Method

Results

Findings

• Shape: 7

• 3D ROI

• Acc: 0.81

Shape

• SMOTE

• Sen: 0.67

• CIFE

• Spe: 0.87

• RF

• AUC: 0.87

renal

tumors (N = 177)
using four phases

– Phase 1 & 4: 7
• 1 st Order Statistics: 4

of CECT images

median,

Demirjian

Grading and stag-

et al. [119]

ing of ccRCC renal tumors (N =

extracted

Phase 1 & 4 of

(AUC

Pctl,

using RF

90th

Pctl

tics:
intensity
–

the best ccRCC

10th

– 1 st Order Statis-

phases of CECT

provided

RMS,

• 3D ROI

2nd

Order Statis-

tics:

• Acc: —

• ICC

• Sen: —

• Gini index

• Spe: —

• RF

• AUC:

• 32% testing

from

grading accuracy

• 5-fold CV

• Grading:

587) using four

images

Order Radiomics

CECT
– Phase 1 & 4: 4

1 st

and

0.73 & 0.77

=

0.87)

Radiomics

ex-

tracted

from

multi-phasic
CECT

could

be

sufficiently

used

to

grade

and stage ccRCC

2D GLCM,

(AUC = 0.73 and

3D GLCM,

0.77) using RF

3D GLRLM
• Staging:
– 2nd Order Statistics:
2D GLCM,
3D GLCM,
2D GLDM,
3D GLDM

Notes

AMLwvf, angiomyolipoma without visible fat; RCC; renal cell carcinoma; CT, computed tomography; GLCM, grey-level co-

occurrence matrix; GLRLM, grey-level run length matrix; GLSZM; grey-level size zone matrix; NGTDM, neighboring gray tone
difference matrix; GLDM, grey-level dependence matrix; ROI, region of interest; SVM, support vector machine; Acc, accuracy, Sen,
sensitivity, Spe, specificity, AUC, area under the curve; CECT, contrast-enhanced CT; std, standard deviation; Phase 1, unenhanced
phase; Phase 2, corticomedullary phase, Phase 3, nephrographic phase, Phase 4, excretory phase; CP, cluster prominence; LRHGE,
long-run high grey-level emphasis; SFS, sequential feature selection; ccRCC, clear-cell RCC; ONC, oncocytoma; TL, transfer learning;
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GTf, Google Tensorflow; chrRCC, chromophobe RCC; Pctl, percentile; RMAD, robust mean absolute difference; MGLA, mean graylevel attenuation; LR, logistic regression; LSSF; Laplacian spatial scaling factor; FFT, fast Fourier transform; paRCC, papillary RCC,
RF; random forests; SMOTE, synthetic minority oversampling technique; RFE, recursive feature elimination; kNN, k-nearest neighbor;
NDA, nonlinear discriminant analysis; Holm-P, Holm-Bonferroni; RFGB, relational functional gradient boosting; LBP, local binary
pattern; DCT; discrete cosine transform; LTE, Law’s texture energy; XGB, extreme gradient boosting; MJV, majority voting; CNN,
convolutional neural network; GLGM, grey-level gradient matrix; ICC, interclass correlation coefficient; RMS, root mean squared;
MLP, multi-layer perceptron; GBDT, gradient boosting decision tree; CMIM, conditional mutual information maximization; CIFE,
supervised feature selection methods;

In summary, the AI-based CAD systems that used CECT images have shown
promising results in early diagnosis of RC, including differentiating malignant from benign tumors with an accuracy range of (41% - 97%) and AUC range of (0.49 - 0.97),
subtyping of RCC tumors with an accuracy range of (47% - 92%) and AUC range of (0.49
- 0.92), grading and staging of RCC tumors with an accuracy range of (70% - 97%) and
AUC range of (0.67 - 0.98). Entropy, a first order texture feature, has been named several
times as one of the most important Radiomic marker that could be extracted from multiphasic CECT. Phase 3, namely; portal-venous/nephrographic phase was the most used and
suggested among all other phases. In addition, SVM, RF, and ANNs classifiers had shown
the best classification results. Although CECT has been proven sufficient for diagnosing
RC, they are not preferred when the radiation exposure is contraindicated (i.e. patient is
pregnant or a child). This motivated researchers to investigate the abilities of other imaging modalities such as MRIs to avoid such radiation exposures, if possible. However,
during our search in the last decade, only limited number of studies were found and thus,
they are discussed in details below.
For differentiating malignant from benign renal tumors, Xu et al. [109] investigated the power of DL and ML on T2-weighted MRI and DW-MRI. A total of 217 patients with renal tumors were included (training = 173 and testing = 44). After manual
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labeling of ROIs, they developed three different DL ResNet-18 models and three different
handcrafted-based RF models on a total of 96 Radiomics markers. The first model was for
T2-weighted alone, the second model was for DW-MRI alone, and the third model was for
the combination between both. They reported an accuracy of 77%, 80%, and 81.3% using
the ResNet-18 models. For the handcrafted-based RF models, they achieved an accuracy
of 77%, 71%, and 82%. Oostenburgge et al. [110] investigated the ability of texture features extracted from the 3D ADC maps of DW-MR images to differentiate benign ONC
from malignant RCC renal tumors. Their study included a total of 39 tumors (RCC = 32
and ONC = 7). They have reported that entropy, STD, tumor volume, and gender were
statistically significant between the different groups. They combined these features to create a logistic regression classification model, which achieved an AUC of 0.91, sensitivity
of 86% and specificity of 84%. In addition, they have found that the 25t h percentile and
entropy are statistically significant when comparing healthy parts from cortex with the tumor. Li et al. [111] utilized DW-MRI to differentiate between malignant and benign renal
tumors. Their study included a total of 92 renal tumors, of which malignant encompasses
(ccRCC = 38, paRCC = 16, chrRCC = 18) and benign encompasses (AML = 13 and ONC
= 7). They generated 3D ADC maps and then extracted 10 different first-order texture features. After making a statistical analysis to find the significant features, they performed
a ROC curve analysis to assess the diagnostic performance. They found that mean, median, 75t h percentile, 90t h percentile, STD, and entropy ADCs of malignant tumors were
significantly higher than benign ones. They reported an AUC of 0.85, sensitivity of 80%,
and specificity of 86.1%. Razik et al. [101] investigated the differentiation between malignant and benign renal tumors using multi-parametric MRIs. Their study included 54 renal
masses (RCC = 34, AML = 14, and ONC = 6) obtained from 42 patients. After placing
2D ROIs on the maximum area of the tumor, they extracted a total of six first-order texture features. Using ROC analysis, they found that mean of positive pixels (MPP) had the
highest diagnostic performance in differentiating RCC from AML with an AUC of 0.89
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on DW-MRI at b-values of 500 s/mm2 . While the mean value was the best feature in differentiating RCC from ONC achieving an AUC of 0.94 on DW-MRI at b-values of 1000
s/mm2 . Nikpanah et al. [169] investigated the power of deep CNNs on T2-weighted MRI,
and multi-phasic CEMRI to differentiate ccRCC from ONC tumors. Their study included
74 patients with 243 renal masses (ccRCC = 203 and ONC = 40). They placed bounding
box (2D ROIs) on the tumors and then feed them to an AlexNet CNN model for diagnosis.
Using a 5-fold cross-validation, they reported an overall accuracy of 91% with an AUC of
0.9. Arita et al. [170] investigated the power of texture analysis on ADC maps extracted
from DW-MRIs to differentiate benign AML from malignant nccRCC renal tumors. Their
study included two datasets. The fist set included 67 tumor (AML = 46 and nccRCC 21) and was used for developing the diagnostic model. While the second one included
39 tumors (AML = 24 and nccRCC = 15) for the validation. They extracted a total of
45 texture features on 3D ADC maps and used a RF classifier to obtain the final results.
Their study reported that long-zone high grey-level emphasis as a second-order texture
feature was the most important and dominant feature to identify AML. The RF classifier
achieved an AUC of 0.82 and was comparable to the radiological assessment. Gunduz
et al. [171] explored the potential of texture analysis on ADC maps extracted from DWMRIs to differentiate benign ONC from malignant chrRCC renal tumors. They included
only 14 patients (ONC = 6 and chrRCC = 8) in their analysis. Their study revealed a total
of six texture features of which five were second-order (short run emphasis, run percentage, normalized run length nonuniformity, run variance, long run emphasis) and one was
first-order (squared root of mean ADC). Using ROC analysis, they have reported 87.5%
sensitivity and 83% specificity. Matsumoto et al. [112] investigated the utility of texture
analysis on DW-MRIs to differentiate benign AML from malignant ccRCC renal tumors.
Their study included two datasets. The fist set included 83 tumor (AML = 18 and ccRCC
= 65) and was used for developing the diagnostic model. While the second one included
39 tumors (AML = 13 and ccRCC = 17) for the external validation. They extracted 39
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texture features from ADC maps and then used a RF model to identify the importance of
the features. Their study revealed that the mean ADC value as a first-order texture feature,
and long-run low grey-level enhancement and grey-level run emphasis as second-order
texture features were of the most dominant features in the diagnostic procedure with an
obtained AUC of 0.87.
For subtyping and grading of RCC tumors, Goyal et al. [100] investigated the role
of texture features extracted from multi-parametric MRIs such as multi-phasic CEMRI,
T1-weighted MRI, T2-weighted MRI, and DW-MRI. Their study included 34 renal masses
(ccRCC = 29 (low-grade = 19 and high-grade = 10) and nccRCC = 5). The 2D ROIs were
placed on the maximum viable tumor. First-order texture features; namely: mean, STD,
MPP, entropy, skewness, and kurtosis, were extracted from each MRI sequence for further
analysis. In subtyping of RCCs and using ROC analysis, entropy achieved an AUC of
0.81 on T2-weighted, STD achieved an AUC of 0.81 and 0.88 on DW-MRI at b-values
of 500 and 1000 s/mm2 , respectively, mean achieved an AUC of 0.848 on ADC, skewness achieved an AUC of 0.85 on T1-weighted an AUC of 0.91 on phase 2 of CEMRI. In
grading of ccRCC renal tumors, entropy achieved an AUC of 0.82 on DW-MRI at b-value
1000 s/mm2 , mean achieved an AUC of 0.89 on phase 2 of CEMRI and MPP achieved
an AUC of 0.87 on phase 3 of CEMRI. They concluded that several first order textural
features extracted from multi-parametric MRIs can be helpful diagnostic tool in both subtyping and grading of renal tumors. Sun et al. [120] investigated the possibility of grading
ccRCC tumors using texture analysis of susceptibility-weighted MR imaging (SW-MRI).
Their study included a total of 45 patients (low-grade = 29 and high-grade = 16). They
reduced the total of extracted texture features from 396 to 10. Then, they build their diagnostic model using a multivariable logistic regression, which achieved an accuracy of
77.3%, sensitivity of 80.5%, and specificity of 71.4%. Chen et al. [121] performed a study
to grade ccRCC tumors using phase 2 of CEMRI. A total of 99 tumors (low-grade = 61
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and high-grade = 38) were included in their study. After placing 2D ROIs, several first-,
second-, and higher-order texture features were extracted and analyzed. The features were
then reduced and selected using RF importance analysis resulting in a total of six texture
features; namely: kurtosis, entropy, sum of entropy, horizontal grey-level nonuniformity,
runlength nonuniformity, and grey-level nonuniformity. Then, they build a MLP-ANN
classification model to obtain the final diagnosis, which achieved 86.2% accuracy, sensitivity of 72.7%, specificity of 94.4%, and an AUC of 0.76 on the validation dataset (N =
29). Although their system was specific, it was not sensitive enough, which can justified
by the class imbalance. Choi et al. [172] investigated the ability of different Radiomic
features including shape features and first- and second-order texture features extracted
from T2-weighted and multi-phasic CEMRI to grade ccRCC renal tumors. Their study
included 364 renal tumors (low-grade = 272 and high-grade = 92). Their RF classification model achieved an AUC of 0.89, accuracy of 98%, sensitivity of 72%, and specificity
of 95%. Although they have achieved an overall good diagnostic performance, the low
sensitivity can be justified by the data imbalance. Uyen et al. [173] investigated the role
of multi-phasic MRI in the differentiation of RCC. Their study included 212 renal lesions
from 36 patients (normal = 96, ccRCC = 87, paRCC = 8, and ONC = 11) of which the
divided into two equal groups, one each for training and validation. After manual placement of 2D ROIs, they extracted first-order texture features (mean, STD, skewness, and
kurtosis). Using a RF classification model, Phase 1 of CEMRI had shown the highest
diagnostic accuracy of 79.1% among all other phases. However, after integrating different
phases an enhanced diagnostic accuracy of 83.7% was obtained. Another study by the
same group [113], investigated the utility of mult-phasic CEMRI to differentiate benign
from malignant renal tumors as well as differentiating common subtypes of RCCs. Their
study include 140 renal lesions from 41 patients (RCC = 90, paRCC = 22, and ONC =
30). They have placed three consecutive 2D ROIs on the slices encompasses the largest
cross-section from each phase of CEMRI. Then, they extracted multiple first- and second-
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order texture features using histogram analysis, GLCM, GLRLM, GLSZM, and NGTDM.
Then, LASSO regression was applied to select the optimal features for classification purposes. They found that first-order texture features were informative in identifying the
malignancy status, while adding the second-order texture features was beneficial in the
subtyping problem. Using RF classification models, they achieved an accuracy of 77.9%
in differentiating paRCC from ccRCC, 79.3% in distinguishing ONC from ccRCC, and
77.9% in differentiating ONC from paRCC.
Table 8 provides summary of the aforementioned AI-based CAD systems that have
been developed, in the last decade, by utilizing different MRI modalities. The Table encompasses the following details: study, main goal, Radiomics, methods, results, and findings.
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TABLE 8: Summary of studies utilized MRIs for renal cancer diagnosis in the last decade.

Study

Main Goal

Radiomics

Method

Results

Findings

Xu

Differentiation of

• Shape: —

• 2D ROI

• Acc: range

Combined

et al. [109]

malignant

from

benign

renal

• 1 st Order Statistics: 1

• ResNet-18

tumors

=

(N

• 2nd Order Statistics: 7

• LASSO

217) using T2weighted

MRI

and DW-MRI

– GLCM: 2

• RF

– GLRLM: 3

• 10-fold CV

– GLSZM: 1

(0.70 - 0.82)
• Sen: range
(0.81 - 0.94)
• Spe: range
(0.33 - 0.92)
• AUC: range

– GLDM: 1

(0.74 - 0.93)

Ra-

diomics extracted
from

multi-

modal

MRIs

have the potential
to

accurately

differentiate
benign

from

malignant

renal

tumors by using
handcraftedbased

RFs

or

DL-based classification models.
•

Oostenburgge Differentiation
et al. [110]

1 st

Order Statistics: 2

of benign ONC
from

malignant

RCC

renal

– entropy

using 3D ADCs

• Acc: 0.87

• LR

• Sen: 0.86

– STD

tu-

mors (N = 39)

• 2D ROI

Radiomics

ex-

tracted from 3D
ADCs such as
standard

• Spe: 0.84

devia-

tion and entropy

• Tumor volume

• AUC: 0.91

of DW-MRIs

when integrated
with tumor volume and gender
can discriminate
ONC from RCC.

• 2D ROI

• Acc: 0.82

– mean

• ANOVA

• Sen: 0.80

mors (N = 92) us-

– median

• ROC analysis

• Spe: 0.86

ing 3D ADCs of

– STD

Li

Differentiation of

et al. [111]

benign from malignant renal tu-

•

1 st

Order Statistics: 6

ADCs of DWMRIs had shown
significantly

– entropy
–

ex-

tracted from 3D

• AUC: 0.85

DW-MRIs

75t h

Radiomics

higher values in
malignant tumors

pctl

than benign ones
(p < 0.05).

– 90t h pctl

Continued on next page
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Study

Main Goal

Radiomics

Method

Results

Findings

Razik

Differentiation

• 1 st Order Statistics: 2

• 2D ROI

• Acc: range

MPP

et al. [101]

of benign from
malignant
tumors

renal
=

(N

• U-test (Statistical

– mean

analysis only)

– MPP

(0.79 - 0.95)
• Sen: range
(0.71 - 0.97)

54) using multiparametric MRIs

• Spe: range
(0.80 - 1.00)

and

mean value can
differentiate RCC
from AML and
RCC from ONC
with an AUC of
0.89

and

at b500
• AUC: range
(0.89 - 0.94)

the

0.94
s/mm2

and b1000 s/mm2
of

DW-MRI,

respectively.
• local ROI patch was au-

Nikpanah

Differentiation

et al. [169]

of ccRCC from

tomatically extracted, size

benign

of 100 × 100 mm.

ONC

renal tumors (N
= 243) using T2weighted

• RGB image patches were

• 2D ROI

• Acc: 0.81

• AlexNet CNN

• Sen: 0.88

• 5-fold CV

• Spe: 0.75
• AUC: 0.90

can

potentially

dif-

tumors
high

configuration.

CEMRI

system

ferentiate ccRCC

fit the pre-trained AlexNet

and multi-phasic

DL-based

from ONC renal

resized to 224 × 224 to

MRI

The

with
diagnostic

performance
on

multi-phasic

MRIs.
Arita

Differentiation

et al. [170]

of benign AML
from

malignant

nccRCC

renal

tumors (N = 106)

•

1 st

Order Statistics: 7

• 2nd Order Statistics: 13
– GLCM: 4

• Acc: 0.77

• RFs

• Sen: 0.87

• 37% validation

• Spe: 0.69

The

long-zone

high

grey-level

emphasis was the
most

important

Radiomic marker
– GLRLM: 4

• AUC: 0.82

using 3D ADCs
of DW-MRIs

• 3D ROI

to

differentiate

– GLSZM: 4

AML from nc-

– GLDM: 1

cRCC on a RF
classifier with an
AUC of 0.82
Continued on next page
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Study

Main Goal

Radiomics

Method

Results

Findings

Gunduz

Differentiation

• 1 st Order Statistics: 1

• 3D ROI

• Acc: 0.86

Squared root of

et al. [171]

between

• ROC analysis

• Sen: 0.88

nant

maligchrRCC

and benign ONC
(N = 14) using
3D

ADCs

– squared root of
mean ADC

mean ADC and
GLRLM
diomic

• Spe: 0.83

markers

of ADC maps can

• 2nd Order Statistics: 5

• AUC: 0.94

of
– GLRLM: 5

DW-MRIs

Ra-

potentially
ferentiate
from

difONC

chrRCC

renal tumors.
• 3D ROI

• Acc: —

– mean ADC

• RF

• Sen: —

benign AML (N

– skewness

• 32% validation

• Spe: —

=

– entropy

Matsumoto

Differentiation

et al. [112]

between

• 1 st Order Statistics: 3

malig-

nant ccRCC and

122)

3D

using

ADCs

Mean
long-run

• 2nd Order Statistics: 9

DW-MRIs

low

grey-level,

• AUC: 0.87

of

ADC,

and

grey-level

run

emphasis

were

the

most

dominant and important Radiomic

– GLCM: 3

markers in differ– GLRLM: 4

entiating

– GLZLM: 1

from ccRCC with
an AUC of 0.87.

– GLDM: 1
Goyal

Subtyping

et al. [100]

grading of malignant
tumors
34)

renal
(N

using

diomic
extracted

and

• 1 st Order Statistics: 6

• 2D ROI
• ROC analysis

– mean

=

– STD

Ra-

– MPP

• Subtyping:

first

order

(0.81 - 0.91)

markers extracted
from

Radiomic

multi-

parametric MRIs

AUC range

– entropy

Several

AUC range

• Grading:

markers
from

AML

(0.82 - 0.89)

can be helpful
diagnostic tool in

multi-parametric

– skewness

both

MRIs

– kutrosis

and grading of

subtyping

renal tumors
Continued on next page
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Study

Main Goal

Sun

Grading

of

et al. [120]

ccRCC

re-

nal

(N

=

tumors
45)

using

Radiomics

Method

Results

Findings

• Shape: 2

• 2D ROI

• Acc: 0.77

Radiomic mark-

• 2nd Order Statistics: 8

• U-test (Statistical

• Sen: 0.81

analysis)
– GLCM: 2

susceptibility-

• ROC analysis

– GLRLM: 1
weighted

MR

imaging

(SW-

MRI)
Chen

Grading

et al. [121]

ccRCC

of

– GLSZM: 2

• LR

– GLDM: 3

• 30% validation

• 1 st Order Statistics: 2

tumors (N = 99)
using Phase 2 of
CEMRI

extracted

from

SW-MRI

can

• Spe: 0.71

provide

a

reliable differen• AUC: 0.81

tiation
low

between
and

high

grades of ccRCC

• 2D ROI

• Acc: 0.86

– entropy

• RF

• Sen: 0.73

– kurtosis

• MLP-ANN

• Spe: 0.94

• 30% validation

• AUC: 0.76

renal

ers

First- and secondorder

Radiomic

markers extracted
from

phase

2

of CEMRI can

• 2nd Order Statistics: 4
– GLCM: 1
– GLRLM: 3

potentially grade
ccRCC

renal

tumors

using

MLP-ANN classification model
Choi

Grading

et al. [172]

ccRCC

of
renal

tumors

=

(N

364) using T2weighted

• Shape: 5

• 3D ROI

• Acc: 0.98

• 2nd Order Statistics: 15

• ANOVA

• Sen: 0.72

• RF

• Spe: 0.95

• 30% validation

• AUC: 0.89

– GLDZM: 15

Proper selection
and

integration

of optimal Radiomic

MRI

markers

extracted

and multi-phasic
CEMRI

MRIs

from

can

po-

tentially help in
grading

ccRCC

renal tumors
Uyen

Differentiation

et al. [173]

of

(Study 1)

RCC

tumors
tumors

• 1 st Order Statistics: 4

images

• Acc: 0.84

– mean

• RF

• Sen: —

– STD

• 50% validation

• Spe: —

renal
renal
(N

=

212) using multiphasic

• 2D ROI

Using a RF classification model,
first-order
diomic

Ra-

markers

extracted

– skewness

• AUC: —

CEMRI
– kurtosis

from

multi-phasic
CEMRI

could

potentially identify RCC renal
tumors.
Continued on next page
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Study

Main Goal

Radiomics

Method

Results

Findings

Uyen

Differentiation

• 1 st Order Statistics: 5

• 2D ROI

• Acc: range

First-order

et al. [173]

of benign from

(Study 2)

malignant

• 2nd Order Statistics: 40

• LASSO

renal

tumors as well

– GLCM: 9

• RF

– GLRLM: 13

• 5-fold CV

as subtyping of
RCC (N = 140)

– GLSZM: 13

(0.78 - 0.79)
• Sen: range
(0.67 - 0.70)
• Spe: range
(0.86 - 0.89)

– NGDTM: 5

• AUC: —

diomic

Ra-

markers

were informative
in

identifying

the

malignancy

status,

while

adding

second-

order

markers

was beneficial in
RCC subtyping

Notes

ADCs, apparent diffusion coefficients; DW-MRIs, diffusion-weighted magnetic resonance images; MPP, mean positive pixels;

GLZLM, grey-level zone length matrix; GLDM, grey-level dependence matrix; GLDZM, grey-level distance zone matrix;

In summary, these AI-based CAD systems that used different types of MRIs have
shown promising results in early diagnosis of RC, including differentiating malignant from
benign tumors with an accuracy range of (77% - 91%) and AUC range of (0.82 - 0.91) and
subtyping and/or grading of RCC tumors with an accuracy range of (77% - 98%) and
AUC range of (0.76 - 0.89). Entropy, mean, MPP, skewness, and kurtosis as first-order
texture features, have been named several times as the most important Radiomic markers extracted from multi-parametric MRIs that could be beneficial to differentiate benign
from malignant renal tumors. Additionally, second-order texture features extracted from
GLRLM are important when added to the aforementioned first-order texture features. In
particular, texture analysis of ADCs on DW-MRI was the most used technique among
these MRI studies. In addition the RF classifiers had been nominated by most of these
studies and shown the best classification results. Although MRIs has been proven sufficient for identifying the malignancy status, subtyping RCCs, grading RCCs, there were
almost no studies investigated the staging of RCCs, which is very important for specifying
the spread of the tumor, size, and location.
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C.

Discussion and Conclusions

Comparing the number of studies performed on CTs to those performed on MRIs,
one can easily justify that by the reduced cost of CTs when compared with MRIs (≈
half the price of the scan). In both cases, they have been shown sufficient for accurate
and early identification of renal tumors, including: malignancy status, subtyping, grading,
and staging. Especially, when using the enhanced phase 3 (portal-venous/nephrographic
phase). In addition, ADC maps of DW-MRIs have been widely used by researchers who
studied texture differences instead of the functionality for RC diagnosis and have been
showing promising results. Radiomics techniques have been proved successful to extract
the most discriminating features that could help in the intended diagnostic problem. AI,
ML, and DL have proved their diagnostic abilities when paired with good discriminatory
features. Entropy, mean, skewness, kurtosis, STD, and median have been proven to be
sufficient for differentiating benign from malignant renal tumors. However, it will not be
the case if these benign tumors are fatpoor AML. Thus, the second-order texture features
extracted from different constructed matrices (e.g., GLCM, GLRLM, GLSZM, GLDM,
and NGDTM) have played an important role here to capture the spatial relationship between neighboring voxels, which might overcome the problem of noisy histogram/firstorder texture features, and thus; might improve the low diagnostic sensitivity that most of
the studies suffer from. Not many studies depended on neither morphological nor functional features, which if integrated will definitely enhance the diagnostic performance.
Several hand-crafted AI-based CAD systems have been presented and a few depended on
DL approaches. The hand-crafted ones have been proven efficient evidenced by high accuracy, sensitivity, and specificity are well-understood (i.e. explainable AI), and therefore
are desirable and dependable. In particular, RFs, SVMs, and MLP-ANNs have provided
impressive diagnostic results and had been accepted by many researchers in the field due
to their ability to handle nonlinear and multi-class classification problems.
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The success of early and accurate diagnosis of the malignancy status of renal tumors, the specific subtype, and the associated grade (I-IV) and stage (I-IV) is of immense
clinical importance as it affects the decision of optimal treatment/management plan. According to the American Cancer Society [15], treatment plans could be one or more of
the following options: Surgery (e.g., radical or partial nephroctomy), Active Surveillance,
Ablation Therapy, Radiation Therapy, Adjuvant Therapy, Targeted Drug Therapy, Immunotherapy, Chemotherapy Therapy, etc. For a given renal tumour with high suspicious
to be malignant, surgical intervention is considered the optimal management plan. Biopsy
is essential to confirm the existence of RCC in the case of: patient is at high risk for
surgery, tumor is locally advanced or became metastatic, before applying ablative therapy,
the patient has a single kidney (original or allograft), or when other malignancy diagnoses
present such as lymphoma or metastasis. In addition, treatment follow-up procedure is crucial to evaluate the clinical outcome/response, the recurrence rate, and the post-operative
progression free-survival (PoPFs) rate as well.
To sum up, more investigative studies are still ongoing for both CTs and MRIs.
Improvement in early diagnosis of renal tumors depend mainly on finding the optimal
discriminating features for the intended diagnostic problem as well as finding the robust
AI-based classification model that could be reproducible and generalizable. Hence, future
research directions focus on building more comprehensive AI-based CAD systems that
can integrate multiple types of features including morphological features to capture the
complexity of the tumor surface and functional features that can describe the functionality through the wash-in/wash-out slopes quantified by the amount of enhancement in the
case of using contrast-based imaging modalities such as CECT and CEMRI. In addition,
functionality can be measured using ADC values in the case of using DW-MRIs. If not
succeeded, multimodal imaging and even histopathology images and genomic markers
might be other possible solutions to be integrated.
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CHAPTER V
RENAL CANCER COMPUTER-AIDED DIAGNOSIS

A.

Materials

Patients who had undergone renal biopsy for suspected cancer (N = 140) ranged
from 15 to 87 years of age (mean = 50.5 years and standard deviation = 13.4 years). There
were 72 patients who were males, while the remaining 68 were female. Informed consent
was obtained from the patients themselves or their parents/legal guardians (age < 18 years)
to participate in this study. Biopsy reports confirmed that 70 patients were malignant with
renal cell carcinoma (RCC) (clear cell RCC (ccRCC) = 40 and non-ccRCC (nccRCC) =
30, of which 17 were papillary RCC and 13 were chromophobe RCC), while the other 70
had benign angiomyolipoma (AML) tumors. Study participants had undergone a multiphase computed tomography (CT) examination prior to biopsy. Imaging was performed
with a Brilliance CT 64 multislice scanner (Philips Medical Systems, Best, The Netherlands). A mechanical injector was used to administer contrast agent into an antecubital
vein with a dose of 120 mL at a rate of 4.0 mL/s. The abdomen scanning included three
main phases: a precontrast phase, a portal-venous phase, and a delayed-contrast phase
acquired at t = 0, t = 80, and t = 300 s, respectively. All images were acquired using the
following parameters: slice thickness = 2.5 mm; pitch = 0.984; rotation time = 0.75 s.
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B.

Methods

FIGURE 15: The proposed renal cancer computer-assisted diagnosis (RC-CAD) system.
The proposed RC-CAD system pipeline (see Figure 15) performs the following
steps to obtain the final diagnosis: (1) constructs 3D models of renal tumors from manually
segmented 2D ROIs, (2) applies applying a new parametric spherical harmonic technique
to estimate the morphological features from the segmented renal tumors to capture the
surface complexity/irregularity between different types of renal tumors, (3) constructs a
rotation-invariant gray-level co-occurrence matrix (GLCM) to extract the textural features
of the tumor volume, (4) estimates the wash-in/wash-out slopes inside the 3D region, and
(5) integrates the estimated morphological features with the first- and second-order textural features and functional features and performs a two-stage classification using MLPANNs whose inputs comprise all aforementioned discriminant features. The first stage
decides if the renal tumor is malignant (RCC) or benign (AML). In the former case, the
second stage identifies the malignancy subtype as ccRCC or nccRCC. These steps are
detailed below.
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1.

Renal Tumor Preprocessing

To provide a more accurate extraction of morphological, textural, and functional
discriminating imaging features, for each subject, each CT slice intersecting the renal
tumor was accurately and manually segmented by expert radiologists to define the 2D
ROI. Then, all 2D ROIs were stacked together to construct the 3D renal tumor object (3D
ROI), as shown in Figure 16.

FIGURE 16: Visualization of the segmentation process to obtain 3D renal tumors.
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2.

Extracting Imaging Features

For accurate identification of malignant renal tumors and the associated subtype,
all 3D segmented volumes were characterized by their morphological, textural, and functional features, as described below.
Morphological features: To enhance both the sensitivity and specificity of early
renal cancer diagnosis, morphological features of the tumor are incorporated into the algorithm. These features were designed to quantify the complex shape of the tumor boundary. This was motivated by the hypothesis that rapidly growing, malignant tumors develop
more irregular/complex shapes relative to more slowly growing, benign tumors. Therefore, the utilization of such shape descriptors would enhance the performance of the automatic diagnosis. Examples of this phenomenon are illustrated in Figure 17.
Naturally, in order to measure the irregularity of the boundary, an accurate shape
model of the tumor must be constructed. In this chapter, a state-of-the-art spectral decomposition was incorporated in terms of spherical harmonics (SHs) [174] to construct
this shape model. An arbitrary point in the interior of the tumor, or more specifically, the
interior of its convex kernel, was selected as the origin (0, 0, 0). In this coordinate system,
the tumor’s surface may be considered a function of the polar and azimuthal angle, f (θ, φ),
which can be expressed as a linear combination of basis functions Yτβ defined on the unit
sphere. Starting with a discrete approximation of the surface, i.e., a triangular mesh, the
proposed algorithm uses an attraction–repulsion technique [175] to map this mesh to the
unit sphere. The mapping fixes the image of each mesh vertex at the unit distance from the
origin, while preserving the mesh topology and maintaining the distance between adjacent
vertices as much as possible.
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FIGURE 17: Visualizing 3D surface complexity differences between different renal tumors (benign are shown in blue, while malignant are shown in red).

Each iteration α of the attraction-repulsion works as follows. Let Cα,i be the coordinates of the node on the unit sphere corresponding to mesh vertex i at the beginning
of iteration α. Denote the vector from node i to node j by dα, ji = Cα, j − Cα,i ; then, the
Euclidean distance between nodes i and j is dα, ji = dα, ji . Finally, let Ji denote the index
set of neighbors of vertex i in the triangulated mesh. Then, the attraction step updates the
position of each node to keep it centered with respect to its neighbors:

C′α+1,i

= Cα,i + CA,1

X
j∈Ji

2
dα, ji dα,
ji

!
dα, ji
+ CA,2
,
dα, ji

(7)

The quantities CA,1 and CA,2 are implementation-defined parameters that determine the
strength of the attractive force. The next step, repulsion, inflates the spherical mesh to
prevent it from degenerating (the attraction step by itself would allow nodes to become
arbitrarily close to one another).
C′′α+1,i

=

C′α+1,i

I
CR X dα, ji
+
,
2I j=1; j,i d2α, ji

(8)

Just as the attraction step, the repulsion step uses an implementation-defined parameter CR
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to set the strength of the repulsive force. Subsequently, the nodes are projected back onto
the sphere by giving them the unit norm, and these are their coordinates at the beginning
of the next iteration, Cα+1,i = C′′α+1,i /∥C′′α+1,i ∥. At the terminal iteration α f of the attraction–
repulsion algorithm, the surface of the renal tumor is in a one-to-one correspondence with
the unit sphere.
Each node Ci = (xi , yi , zi ) of the original mesh is mapped to a corresponding point
Cα f ,i = (sin θi cos ϕi , sin θi sin ϕi , cos θi ) with polar angle θi ∈ [0, π] and azimuthal angle
ϕi ∈ [0, 2π). Considering these points as samples of a continuous function f (θ, φ) defining
the boundary, the tumor shape may be estimated by fitting an SH series to the sample
nodes, since the SHs form an orthogonal basis for functions on a sphere. The SH Yτβ of
degree τ and order β is defined as:





cτβG|β|
−τ ≤ β ≤ −1

τ cos θ sin(|β| φ)







 cτβ |β|
Yτβ = 

√ G τ cos θ
β=0

2









cτβG|β|
1≤β≤τ
τ cos θ cos(|β| φ)

(9)

where cτβ is the SH factor and G|β|
τ is the associated Legendre polynomial of degree τ and
order β.
In practice, of course, the SH series is truncated by discarding harmonics above
degree N, yielding an Nth order approximation. N = 70 suffices to accurately model the
surface of renal tumors. Finally, the renal tumor object is reconstructed from the SHs
of Equation (9). The first few harmonics describe the rough extent of the tumor, while
higher degree harmonics provide the finer details of its surface. Therefore, benign tumors
are accurately represented by a lower-order SH model, while malignant tumors, with their
more complex morphology, require higher-order SH model to describe their shape.
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Figure 18 shows the morphology approximation for three different renal tumors:
malignant ccRCC, malignant nccRCC, and benign AML tumors. A summary of the
attraction–repulsion algorithm is provided below.

FIGURE 18: Renal tumors’ reconstruction meshes showing the morphological differences
among malignant ccRCC, malignant nccRCC, and benign AML tumors.

Initialization:
• Triangulate the surface of the tumor.
• Smooth the triangulated mesh with Laplacian filtering.
• Initialize the spherical parameterization with an arbitrary, topology-preserving map
onto the unit sphere.
• Fix values of CA,1 , CA,2 , CR , and threshold T .
Attraction–repulsion:
• For α = 0, 1, . . .
– For i = 1, . . . , I
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′
* Calculate Cα+1,i using Equation (7)

– For i = 1, . . . , I
′′
* Calculate Cα+1,i using Equation (8)
′′
′′
* Let Cα+1,i = Cα+1,i /∥Cα+1,i ∥

– If maxi ∥Cα+1,i − Cα,i ∥ ≤ T Then, let α f = α + 1, and Stop.

Textural features: Recently, TA has become a popular research topic, particularly in the field of medical imaging. New techniques of TA provide different quantitative patterns/descriptors by combining the grey values of each pixel/voxel in a tumor
image/volume. As a result of these abilities, TA has been used in the diagnosis of several
tumors and their related subtypes with encouraging classification abilities [104, 105, 176–
182]. Therefore, in this chapter, TA techniques were applied on the segmented 3D renal tumor volumes to precisely extract first- and second-order textural features that best
describe the homogeneity/heterogeneity between renal tumors with different diagnoses.
The use of such comprehensive textural features relies on the fact that malignant tumors
mostly show high textural heterogeneity when compared to benign ones. The success of
these findings would enhance the sensitivity and the specificity towards an early identification of renal cancer tumors. Figure 19 demonstrates the lesion texture differences of
two malignant ccRCC subjects, two malignant nccRCC subjects, and two benign (AML)
subjects.
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FIGURE 19: An illustrative example showing differences in texture between various renal
tumor types.
First-order textural features: These textural features include any quantity that
can be derived from the gray-level histogram of the tumor volume. In particular, mean,
variance, standard deviation, entropy, skewness, kurtosis, cumulative distribution functions, and the grey-level percentiles [183] were extracted.
Figure 20 shows the average normalized histogram curves for all benign subjects
(blue) vs. malignant (red). To construct these curves, the grey-level range was normalized
first by dividing by the maximum grey-level value obtained from all subjects. Then, all
histograms were constructed for all subjects within the new normalized grey-level range
from 0 to 255. For each subject, the individual grey-level probability was obtained by
dividing the histogram values by the corresponding number of voxels. Then, all normalized histograms from a particular group (malignant or benign) were averaged pointwise to
obtain the final curve.
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FIGURE 20: A visualization of the average normalized histogram curves for all benign
subjects (blue) vs. malignant (red).

Second-order textural features: Since the first-order textural features might not
be sufficient, with their range of values exhibiting significant overlap across classes, especially between subtypes of malignant tumor, second-order textural features were incorporated into the system. These features describe the joint distribution of gray values
in multiple voxels that are considered to be neighbors of each other. In particular, the
grey-level co-occurrence matrix (GLCM) [184] was used to capture the heterogeneous
appearance of renal tumors.
To construct the GLCM, the number of times an ordered pair of two grey values
occurs in two neighboring voxels within the renal tumor object must be counted. This
technique is continued until all conceivable occurrence frequencies within the grey-level
range of the renal tumor item are found, which covers all possible pairs of neighbors. For
this, the renal tumor object’s original grey-level range was first first contrast stretched to
fit the desired span 0–255, yielding a GLCM matrix with a size of 256 × 256. Then,
all feasible pair combinations were identified to construct the GLCM matrix (i.e., neigh96

bors with gray levels i and j contribute to row i, column j of the GLCM). To define the
√
neighborhoods, a distance criterion that voxels must be separated by ≤ 2 mm was used,
making the calculations rotation invariant (see Figure 21). The resultant GLCM was then
normalized and used to extracting the following second-order texture features [183, 184]:
contrast, dissimilarity, homogeneity, angular second moment (ASM), energy, and correlation.

FIGURE 21: Visualization of the rotation-invariant neighborhood calculation system used
to construct the grey-level co-occurrence matrix (GLCM). The GLCM can be constructed
by counting the occurrence frequency of different grey-level pairs in-plane and in adjacent
planes accounting for the 26-neighbor voxels (blue) of the central voxel (red).

The definitions of all first- and second-order textural features are provided in Tables 9 and 16 in Appendix .A.
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Functional features: Discriminating RCC from AML, as well as ccRCC from
nccRCC might be achieved using time-dependent characteristics of CE-CT imaging. The
most relevant CE-CT findings for this purpose are generally homogenous and prolonged
enhancement patterns [185]. The time dependency can be expressed by the slopes of
wash-in and wash-out. Wash-in is described as the rate of increasing attenuation (in HU)
from the precontrast to portal-venous phase. Similarly, wash-out is the rate of decrease
in attenuation between the portal-venous and delayed-contrast phase [186]. Higher slopes
of wash-in and wash-out are typically associated with malignancy. Moreover, nccRCC
demonstrates wash-in and wash-out slopes intermediate between those of AML and those
of ccRCC [187]. Therefore, both wash-in and wash-out slopes were constructed for all
renal tumor subjects for the classification of the renal tumor status. Examples of washin/-out slopes showing the differences across ccRCC, nccRCC, and AML are shown in
Figure 22.

FIGURE 22: Example of the wash-in and wash-out slopes construction process for various types of renal tumors. When compared to nccRCC (green) and AML (blue), ccRCC
tumors exhibit higher and faster wash-in/-out slopes (red).
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TABLE 9: Definition of first- and second-order textural features.
Textural Feature

Definition
First Order

Mean

The average grey value of voxels within the tumor.

Variance

Second central moment of gray values.

Standard deviation

Square root of variance.

Skewness (Skew)

Asymmetry of the distribution of gray values about the mean. If Skew
< 0, that means the grey-level spreads out more to the left of the mean
than to the right and if Skew > 0, that means the grey-level spreads out
more to the right of the mean than to the left. Skew will equal to zero in
the case of normal distributions.

Kurtosis (Kurt)

Measures the tail weight, or tendency to extreme values, of the object
grey-level distribution. The normal distribution has Kurt = 3; distributions with heavier tails have Kurt > 3, and distributions with less weight
in the tails have Kurt < 3.

Entropy

A measure of randomness of grey values with in an input image.

CDFs

A distribution function that accumulates voxel-wise grey values from
the whole tumor with minimum value = 0 and maximum value = 1.

Percentiles

Grey values percentiles corresponding to the CDFs (from 10% to 100%)
Second Order

Contrast

Measures the disparity in grey-level values between neighbors.

Dissimilarity

Finds to what extent voxels are different from their neighbors.

Homogeneity

Expresses the inverse difference moment among neighbors.

Angular second moment (ASM)

Determines the gray-levels local uniformity (orderliness).

Energy

The square root of the ASM.

Correlation

Determines the grey-level linear dependency in neighborhood blocks.
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3.

Feature Integration and Renal Tumor Classification

Following the extraction of morphological, textural, and functional features from
all given renal tumors, RC-CAD proceeds with two-stage diagnostic classification. The
first stage aims to differentiate malignant (RCC) from benign (AML) tumors. In the case
of malignancy, the second stage provides the classification of RCC tumors as ccRCC
or nccRCC.
The multilayer perceptron (MLP) artificial neural network (ANN) consists of at
least three layers: an input layer, one or more hidden layers, and an output layer, each
with arbitrarily many activation/processing units, known as nodes/neurons. Each layer is
fully connected to the next layer in sequence. Neurons use nonlinear activation functions
to give the MLP-ANN the capability to divide the feature space into arbitrarily complex
regions. The MLP-ANN mainly utilizes supervised backpropagation learning technique
in the training phase, in which gradient descent methods are utilized to update the connection weights and additive biases in order to minimize the loss function. To achieve the
goal, the MLP-ANN was optimized in both classification stages to obtain the final diagnosis. Classifier performance was assessed using five different feature sets (Table 10) as the
ANN input in both stages. Feature Set 1 includes first-order histogram textural features
(N = 6; mean, variance, standard deviation, skewness, kurtosis, and entropy); Feature Set
2 includes first-order percentile textural features (N = 10; from the 10th to the 100th percentile in 10% point steps); Feature Set 3 includes second-order GLCM textural features
(N = 6; contrast, dissimilarity, homogeneity, ASM, energy, and correlation); Feature Set
4 includes SH reconstruction error (SHRE) morphological features (N = 70); and Feature
Set 5 includes functional features (N = 2; wash-in slope and wash-out slope). At each
classification stage, the individual feature sets were concatenated to obtain the combined
features (N = 94) and were fed to a MLP-ANN to obtain the final diagnosis.
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TABLE 10: Details of the extracted feature-sets used in the two-stage renal tumor classification.
Texture features
Feature-Set 1: First order (Histogram features)

6 features

Feature-Set 2: First order (Percentiles)

10 features

Feature-Set 3: Second order (GLCM)

6 features

Shape features
Feature-Set 4: Spherical Harmonics Reconstruction Errors

70 features

Functional features
Feature-Set 5: Wash-In/Out slopes

2 features

Combined Features
Feature-Sets 1, 2, 3, 4, and 5

94 features

C.

Results

The diagnostic performance of the RC-CAD system on the dataset of 140 renal tumors was assessed using leave-one-subject-out (LOSO) cross-validation. The system’s diagnostic capabilities were assessed, evaluated, and compared in both classification stages
using the individual feature sets, as well as the combined features. Each classification process was repeated 10 times, and the results were tabulated in terms of the mean ± the standard deviation to provide a more quantitative expression of the diagnostic performance.
The first stage classification (RCC vs. AML) performance for the RC-CAD system
was first evaluated using individual Feature Sets 1, 2, 3, 4, and 5 (see Table 10) along
with different MLP-ANN classification models. Then, the RC-CAD system was evaluated
using the combined features, resulting in a noticeably enhanced diagnostic performance.
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A summary of the first stage performance in terms of the sensitivity, specificity, and Dice
similarity coefficient (DSC) [188, 189] is presented in Table 11.

TABLE 11: Diagnostic performance results of the first stage classification (RCC vs.
AML) using different individual feature-sets along with multi-layer perceptron artificial
neural network (MLP-ANN) classification models. The RC-CAD system diagnostic performance using the combined features outperformed the diagnostic abilities using individual feature-sets. Sens: sensitivity, Spec: specificity, DSC: Dice coefficient of similarity,
hln : size of hidden layer n.
RCC vs. AML Classification Performance (Mean±SD ≈)
Feature-Set

Sens%

Spec%

DSC

MLP-ANN

Set 1

94.1±1.5

97.9±1.5

0.96±0.01

hl1 = 10 nodes

Set 2

92.4±2.9

95.1±3.5

0.94±0.02

hl1 = 10 nodes

Set 3

94.9±2.2

95.3±2.5

0.95±0.02

hl1 = 10 nodes

Set 4

92.0±2.4

96.6±2.0

0.94±0.02

hl1 = 10 nodes, hl2 = 5 nodes

Set 5

82.7±4.1

91.7±2.0

0.87±0.02

hl1 = 10 nodes

RC-CAD

95.3±2.0

99.9±0.4

0.98±0.01

hl1 = 50 nodes, hl2 = 25 nodes

Hyper-parameters: MLP-ANN (optimization function: trainlm, max epochs = 500, goal = 0, max
validation failure = 6, min gradient = 10−7 , training gain (µ): initial µ = 0.001, µ decrease factor = 0.1, µ
increase factor = 10, max µ = 1e10 ).

The diagnostic performance of the second stage classification (ccRCC vs. nccRCC) of the RC-CAD system was evaluated using the same LOSO cross-validation approach. As before, specially tailored MLP-ANN models were used with different feature
sets. The best second stage classifier performance was obtained using the concatenated
feature set (Table 12).

102

TABLE 12: Results from the second stage classification (ccRCC vs. nccRCC) using individual feature-sets (1, 2, 3, 4, and 5) along with multi-layer perceptron artificial neural
networks (MLP-ANN) classification models. The RC-CAD system diagnostic performance using the combined features outperformed the diagnostic abilities using individual
feature-sets. Acc: accuracy, hln : size of hidden layer n.

ccRCC vs. nccRCC classification Performance (Mean±SD ≈)
Feature-Set

Acc%

MLP-ANN Architecture

Set 1

76.8±2.6

hl1 = 10 nodes

Set 2

75.7±3.8

hl1 = 10 nodes

Set 3

83.3±5.6

hl1 = 10 nodes

Set 4

81.4±5.1

hl1 = 10 nodes, hl2 = 5 nodes

Set 5

76.2±2.33

hl1 = 10 nodes

RC-CAD

89.6±5.0

hl1 = 50 nodes, hl2 = 25 nodes

Hyper-parameters: MLP-ANN (optimization function: trainlm, max epochs = 500, goal = 0, max
validation failure = 6, min gradient = 10−7 , training gain (µ): initial µ = 0.001, µ decrease factor = 0.1, µ
increase factor = 10, max µ = 1e10 ).

Figure 23 demonstrates a difficult case presentation for two ccRCC, two nccRCC,
and two AML renal tumors. This figure visualizes the texture differences, wash-in and
wash-out slope differences, and morphological differences between the different types of
renal tumors, which emphasizes the potential power of the integration process of such features in providing a precise identification of a given renal tumor.
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FIGURE 23: A difficult case presentation showing the textural differences, wash-in and
wash-out slope differences, and shape differences between two ccRCC, two nccRCC, and
two AML renal tumors.
To ensure that the developed system is not prone to overfitting and to validate
the reproducibility and robustness of the RC-CAD, a randomly stratified 10-fold crossvalidation approach was employed in both stages using the combined features. Likewise,
the classification process was repeated 10 times using the same MLP-ANN classification
model, and results are tabulated in terms of the mean ± the standard deviation (Table 13).
To highlight the advantages of using MLP-ANN classifier, the diagnostic performance of the RC-CAD was compared with other, well-known machine learning classifiers
(e.g., SVMQuad and RF). As documented in Table 13, the diagnostic performance obtained
by the RC-CAD system outperformed all other classifiers in both classification stages,
which justifies the potential of such MLP-ANN classifiers being utilized for the developed
RC-CAD system. It is worth mentioning that, in each classification stage, a grid search
algorithm was employed to find the optimal set of hyperparameters, with the classification
accuracy optimization criterion, for each of the classifier techniques being evaluated. The
results of the hyperparameter optimization are appended to Table 13.
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TABLE 13: Diagnostic performance comparison for both classification stages between
the developed RC-CAD system and other classification approaches (e.g., random forest
(RF) and support vector machine (SVM)). Using leave-one-subject-out (LOSO) and a
randomly stratified 10-fold cross-validation approach, the diagnostic abilities of the RCCAD outperformed others. Let Sens: sensitivity, Spec: Specificity, DSC: Dice similarity
coefficient, and Acc: Accuracy.
First Stage Classification (RCC vs. AML) Performance (Mean±SD ≈)
Method

Validation

Sens%

Spec%

DSC

LOSO

95.3±2.0

99.9±0.4

0.98±0.01

10-fold

89.0±3.4

91.0±2.7

0.90±0.02

LOSO

89.0±1.7

92.7±2.7

0.91±0.02

10-fold

88.4±1.0

90.7±3.0

0.89±0.01

LOSO

82.9±0.0

88.6±0.0

0.85±0.00

10-fold

81.9±2.2

87.7±2.5

0.84±0.02

RC-CAD (Proposed)

RFs

SVMQuad

Second Stage Classification (ccRCC vs. nccRCC) Performance (Mean±SD ≈)
Method

Validation

Acc%

LOSO

89.6±5.0

10-fold

78.6±5.7

LOSO

53.7±3.7

10-fold

51.9±2.6

LOSO

52.9±0.0

10-fold

54.3±3.0

RC-CAD (Proposed)

RFs

SVMQuad

Hyper-parameters: MLP-ANN (optimization function: trainlm, max epochs = 500, hidden layers: hl1 = 50
nodes, hl2 = 25 nodes, goal = 0, max validation failure = 6, min gradient = 10−7 , training gain (µ): initial µ
= 0.001, µ decrease factor = 0.1, µ increase factor = 10, max µ = 1e10 ); RF (method: Bag, number of
learning cycles = 30); SVM (kernel function: quadratic, box constraint = 1).

105

For the comparison with the RC-CAD, the existing state-of-the-art approach [123]
was applied using a total of 10 textural markers extracted from the portal-venous phase
only along with the gradient boosting classification technique. In addition, the state-ofthe-art deep learning CNN approaches proposed by Lee et al. [128] and Oberai et al. [133]
were applied on the same datasets (first stage: N = 140; second stage: N = 70). To highlight the advantages of the RC-CAD system, all results are compared in Table 14. The
diagnostic performance of RC-CAD exceeded that of other approaches in both classification stages.
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TABLE 14: Diagnostic performance comparison for both classification stages between the
developed RC-CAD system and other state-of-the-art approaches. The diagnostic abilities
of the RC-CAD outperformed all other methods in both classification stages. Let Sens:
sensitivity, Spec: Specificity, DSC: Dice similarity coefficient, and Acc: Accuracy.
First Stage Classification (RCC vs. AML) Performance (Mean±SD ≈)
Method

Sens%

Spec%

DSC

RC-CAD (Proposed)

95.3±2.0

99.9±0.4

0.98±0.01

Kunapuli [123]

81.4±0.0

95.7±0.0

0.88±0.00

Oberai [133]

88.9±1.7

87.4±1.4

0.91±0.01

AlexNet

84.0±1.7

93.4±1.9

0.88±0.02

GoogleNet

88.3±1.7

95.1±1.9

0.91±0.01

ResNet

88.0±3.5

95.7±0.9

0.91±0.02

VGGNet

86.9±0.6

91.4±2.4

0.89±0.01

Lee [128]

Second Stage Classification (ccRCC vs. nccRCC) Performance (Mean±SD ≈)
Method

Acc%

ccRCC/40

nccRCC/30

RC-CAD (Proposed)

89.6±5.0

35±2

28±3

Kunapuli [123]

60.6±2.7

28±1

15±1

Oberai [133]

84.3±3.1

34±1

25±2

AlexNet

71.7±1.9

31±2

19±2

GoogleNet

68.0±1.5

32±1

15±1

ResNet

70.3±2.5

32±0

17±2

VGGNet

72.6±2.3

33±1

18±1

Lee [128]

Hyper-parameters: MLP-ANN (optimization function: trainlm, max epochs = 500, hidden layers: hl1 = 50
nodes, hl2 = 25 nodes, goal = 0, max validation failure = 6, min gradient = 10−7 , training gain (µ): initial µ
= 0.001, µ decrease factor = 0.1, µ increase factor = 10, max µ = 1e10 ).
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D.

Discussion and Conclusions

The developed RC-CAD system demonstrated high diagnostic performance in terms
of accuracy, sensitivity, specificity, and DSC in discrimination between benign (AML) and
malignant (RCC) and in classification of the RCC subtype into ccRCC or nccRCC. This
early and precise identification of the malignancy status of a given renal tumor and its associated subtype can enable clinicians to provide the appropriate early intervention/treatment
plan and improve the outcomes. CE-CT was utilized as it is an imaging modality with the
ability to provide different aspects of features, including but not limited to, morphological
features, textural features, and functional features. The integration of these features is effective in determining the malignancy status of a given renal tumor when combined with
a powerful machine learning classifier such as the MLP-ANN.
The grade of malignancy of a given renal tumor largely specifies the morphology
of the tumor. Typically, malignant tumors demonstrate a more complex morphology than
benign ones. Therefore, morphological features based on using spherical harmonics were
utilized to capture possible surface complexity differences between malignant and benign
renal tumors, as well as differences between different subtypes of malignancy.
First- and second-order textural features have been widely utilized to identify a
given renal tumor status as malignant or benign, as well as to describe the malignancy
subtype [122, 123, 125, 127, 128, 134]. These features capture all possible textural homogeneity/heterogeneity across renal tumors with different diagnoses. In line with these studies, the extracted textural features provided high diagnostic performance in discriminating
malignant ccRCC and nccRCC from benign (AML) renal tumors.
Additionally, functionality was utilized to identify the malignancy status renal tumors. The wash-in and wash-out slopes can capture existing differences in the enhance-
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ment characteristics [185, 186]. In this study, the results obtained by functionality metrics
demonstrated the efficacy of such features in discriminating between benign (AML) and
malignant (RCC) and identifying the malignancy subtype as ccRCC or nccRCC.
Although individual features have provided a reasonable diagnostic performance,
they are not sufficient to rule out surgical intervention in (what may turn out to be) benign lesions. Therefore, the integration process of these features is critical to enhance
the diagnostic accuracy to the point of clinical utility. The integration process produced a
reliable and accurate RC-CAD system with an enhanced diagnostic performance in both
classification stages as documented in Tables 11–13.
To sum up, the developed RC-CAD system demonstrated a high classification sensitivity of 95.29% ± 2.03%, a specificity of 99.86% ± 0.43%, an ad DSC of 0.98 ± 0.01 in
differentiating benign AML from malignant RCC renal tumors. In addition, the RC-CAD
achieved an overall classification accuracy of 89.57% ± 5.03% in distinguishing ccRCC
from nccRCC to provide the proper management plan. Integrating accurate morphological features with functional features and multiple first-order and second-order textural
features was adequate to significantly enhance the diagnostic capabilities.
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CHAPTER VI
CONCLUSIONS AND FUTURE WORK

This dissertation presented a new computer-assisted diagnostic (Renal-CAD) system to precisely diagnose acute rejection (AR) post kidney transplantation at an early
stage. The Renal-CAD system demonstrated 93.3% accuracy, 90.0% sensitivity, and
95.0% specificity in differentiating AR from non-rejection (NR). Robustness of the RenalCAD system was also confirmed by the area under the curve value of 0.92. In addition,
a new renal cancer CAD (RC-CAD) system for precise diagnosis of RC at an early stage
was developed. The RC-CAD achieved a sensitivity of 95.3% ± 2.0%, a specificity of
99.9% ± 0.4%, and Dice similarity coefficient of 0.98 ± 0.01 in differentiating malignant
from benign renal tumors, as well as an overall accuracy of 89.6% ± 5.0% in the subtyping
of renal cell carcinomas (RCCs). The results obtained outperformed other machine learning classifiers as well as other different approaches from the literature. Machine learning
and deep learning approaches have shown potential abilities to be utilized to build such
AI-based CAD systems. This is evidenced by the promising diagnostic performance obtained by both Renal-CAD and RC-CAD systems. For the Renal-CAD, the integration of
functional markers extracted from multimodal MRIs with clinical biomarkers using deep
learning-based stacked autoencoder (SAE) classification model, potentially improved the
final diagnostic results evidenced by high accuracy, sensitivity, and specificity. The developed Renal-CAD demonstrated high feasibility and efficacy for early, accurate, and
non-invasive identification of AR. For the RC-CAD, integrating morphological, textural,
and functional features extracted from CE-CT images using a machine learning-based
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multi-layer perceptron artificial neural network (MLP-ANN) classification model eventually enhanced the final results in terms of accuracy, sensitivity, and specificity, making the
proposed RC-CAD a reliable noninvasive diagnostic tool for renal cancer (RC). The early
and accurate diagnosis of AR and/or RC will help physicians to provide early intervention with the appropriate treatment plan to prolong the life span of the diseased kidney,
increase the survival chance of the patient, and thus improve the healthcare outcome in the
U.S. and worldwide.

A.

Summary of Contributions

Main contributions of this dissertation are summarized in the following pullets:

• A new AI-based CAD system was developed to precisely diagnose AR post kidney
transplantation at an early stage. The developed system was named Renal-CAD and
encompasses the following contributions:
– Extraction of DW-MR image markers, namely: voxel-wise apparent diffusion
coefficients (ADCs) are calculated from the segmented kidneys at 11 different low and high b-values and then mapped to their cumulative distribution
functions (CDFs) for better representation.
– Extraction of BOLD-MR image markers, namely: the transverse relaxation
rate (R2*) values from the segmented kidneys at four different echotimes and
then R2* curves were constructed for better representation.
– Integrating the extracted multimodal MR image markers with the associated
clinical biomarkers serum creatinine (SCr) and creatinine clearance (CrCl).
These integrated biomarkers are then fed to the developed DL classification
model built on SAEs to diagnose the kidney transplant as NR or AR.
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• A new AI-based CAD system for precise diagnosis of RC at an early stage was developed. The developed system was named RC-CAD and incorporates the following
major contributions:
– Integrating the morphological features the best describe the surface complexity
of a given renal tumor, with first and second order appearance-based features
that can capture the texture heterogeneity of a given renal tumor, and with the
functional features by constructing wash-in/wash-out slopes to quantify the
enhancement variations across different CE-CT phases.
– Modeling a two-stage MLP-ANN classifier using the aforementioned integrated features to diagnose the renal tumor as benign or malignant and identify
the malignancy subtype.

B.

Future Avenues

The success of both AI-based CAD systems (Renal-CAD and RC-CAD) presented
in this dissertation opens research pathway and thoughts towards some future avenues:
• Increasing the number of kidney transplant patients who had both types of scans
(i.e. DW-MRI and BOLD-MRI). In this study, only the DW-MRI analysis pipeline
included data from different geographical areas; and thus, more data could be collected for further validation, optimization, and fine tuning.
• The abilities of the Renal-CAD system could be extended (see Fig. 24 by adding
genomic markers and proteomic markers to identify different types of AR post
kidney transplantation as T-cell mediated rejection (TMR) or antibody mediated
rejection (AMR). These specific identification will enhance the Renal-CAD diagnostic abilities, help in administering a timely intervention with the appropriate
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treatment/management plan, prolong the survival rate of the transplanted kidney,
improve the patient outcomes, and thus, improve the healthcare in the U.S. and
worldwide.

FIGURE 24: Suggested pipeline for identifying the AR subtype as TMR or AMR.
• The abilities of the Renal-CAD could also be investigated to identify additional renal
dysfunction conditions such as nephrotic syndrome, acute tubular necrosis, tubular
inflammation, acute kidney injury, and other chronic kidney diseases that might
affect either the native or the transplanted. Integration of histopathology images,
DNA, and RNA analysis could potentially help.
• Investigate the abilities of the RC-CAD system in identifying other tumors such as
oncocytomas. Although they are benign tumors. they usually have a central scar
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and showing similar characteristics of malignant tumors, specifically chromophobe
RCC, which in turn make the differentiating between oncocytomas and chromophobe a challenging task.
• The abilities of the RC-CAD system to differentiate papillary RCC from chromophobe RCC will be investigated.
• Automatic detection, localization, and segmentation of renal tumors is very challenging for many reasons, including: (1) the wide variety in renal tumors size, some
of them are very small (≤ 4 cm) and some of them are very large and can cover
large portions of the abdomen and (2) different locations, they could be on the right
side, left side, different locations of the kidney (upper, middle, or lower) portion.
Thus; most of the studies still depend on expert knowledge to segment the renal
tumor manually using some segmentation tools before the handcrafted features are
extracted.
• Development of an end-to-end AI-based CAD system is an ongoing research. Such
systmes utilize deep learning techniques (e.g., convolutional neural networks (CNNs))
and could be one of the solutions that can provide the final diagnosis from an input
image without the need for manual segmentation or hand-crafted features.
• Multi-parametric MRIs are other imaging modalities that could be used for diagnosing RC, especially in the cases when the patient is pregnant or a child, then there is
no need to expose them to radiation.
• Potential investigation of an AI-based CAD system that integrate multi-modal imaging Radiomic makers extracted from CTs and MRIs could be helpful in accurate
grading (I-IV) and staging (I-IV) of renal tumors to determine how aggressive the
tumor is and the exact location of the tumor. These findings will help administering
appropriate intervention and treatment plans in a timely manner.

114

• The abilities of the RC-CAD systems could be extended (see Fig. 25) to predict the
treatment response such as recurrence rate, post-operative progression free-survival
rate, or good response. This prediction will help physicians/oncologists in determining the treatment outcome and thus, recommend the change of therapy course
or not.

FIGURE 25: Suggested pipeline for: (1) identifying the malignancy status of a given
renal tumors, malignancy subtyping, grading (I-IV), and staging (I-IV) and (2) prediction
of treatment response.

• This work could also be applied to various other applications in medical imaging,
such as the prostate [190–216], the kidney [33, 72, 217–244, ?–258], the heart [259–
294], the lung [174, 295–348], the brain [349–432], the retina [433–448], the bladder [449–455], the liver [456–458], head and neck [459–462], and injury prediction [463] as well as several non-medical applications [464–471].
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APPENDIX1

A.

Mathematical Formulas for Textural Features

In this appendix, we are going to detail the mathematical formulas used to extract
the textural features:

Basic Notation

• µ: Mean.
• n: Total number of Voxels in the object.
• vi : Gray-level value of Voxel i.
• σ2 : Variance.
• σ: Standard deviation.
• Ng : The normalized grey-levels.
• p: The normalized histogram counts.
• ϵ: An initial random small number.
• Ng : Grey-levels (normalized 0–255).
• G N : The GLCM (normalized 0–1).
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TABLE 15: First order texture features formulas.
Feature

Formula

n

Mean (µ)

v1 + v2 + · · · + vn
1X
vi =
n i=1
n

Pn

Variance

i=1 (vi

(σ )

(Ent)

Skewness
(Skew)

Kurtosis
(Kurt)

(11)

n

2

Entropy

− µ)2

−

Ng
X

p(i) log2 p(i) + ϵ

(10)



(12)

i=1

n

1 X  vi − µ 3
n i=1
σ

(13)

n

1 X  vi − µ 4
n i=1
σ

• x̄, σ x (i): The row margins (mean and standard deviation).
• ȳ, σy (i): The column margins (mean and standard deviation).
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(14)

TABLE 16: Second order texture features formulas.
Feature

Formula

Ng X
Ng
X

Contrast

(i − j)2G N (i, j)

(15)

i=0 j=0

Dissimilarity

Ng X
Ng
X

|i − j|G N (i, j)

(16)

i=0 j=0

Ng X
Ng
X
G N (i, j)
1 + (i − j)2
i=0 j=0

Homogeneity

Ng X
Ng
X

ASM

2
G N (i, j)

(17)

(18)

i=0 j=0

√
AS M

Energy

PNg PNg
i=0

Correlation

j=0 G N (i,

j)i j − x̄ȳ

σ x (i)σy ( j)
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